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Preventing, delaying and managing morbidities is critical to sustain a strong 
economy and health care system as the proportion of adults over 65 years 
increases.  Cardiovascular disease (CVD) is the leading cause of morbidity and 
mortality in Americans. Signs of CVD are apparent in the vasculature before 
symptoms of clinical disease are present.  Subclinical disease can be measured 
using non-invasive B-mode ultrasound to assess carotid-femoral pulse wave 
velocity, common carotid artery intima media thickness, adventitial diameter 
and lumen diameter.  Vascular aging is a natural process that can be modified 
by lifestyle and pharmacologic interventions.  The purpose of this dissertation is 
to evaluate the impact of lifestyle factors on vascular aging. 
 
Hormone therapy use in early postmenopausal women was associated with 
significantly smaller adventitial and lumen diameter than those who did not use 
hormone therapy after adjustment for traditional CVD risk factors.  These results 
concur with findings from another study in which higher levels of endogenous 
estrogen was related to smaller adventitial diameters. Together, these results 
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suggest endogenous and exogenous estrogen have similar effects on 
adventitial diameter. 
 
Sedentary, overweight and obese male young adults at low risk of sleep apnea, 
and non-snorers had better vascular health, reflected in smaller adventitial and 
lumen diameters, than those at high risk for sleep apnea and snorers in a cross-
sectional study.  Results were robust after adjustment for age and systolic blood 
pressure and add to the literature linking CVD with sleep disordered breathing.  
 
Sedentary older adults who participated in a 6-month physical activity 
intervention had a clinically relevant decline in arterial stiffness, but greater 
increases in adventitial and lumen diameters compared to control participants. 
These findings support that it is never too late to gain cardiovascular benefit 
from physical activity. Research is needed to understand the implications of 
arterial diameter following introduction of physical activity to sedentary older 
adults. 
 
Together these studies support the public health importance of lifestyle factors 
contribution to subclinical CVD. Each study also provides evidence that 
measurement of adventitial diameter is critical for a comprehensive 
understanding of the vascular remodeling processes that accompany these 
lifestyle changes across the vascular aging continuum. 
vi 
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS ................................................................................................ XII 
1.0 DISSERTATION OVERVIEW AND OBJECTIVE ................................................... 1 
2.0 GENERAL INTRODUCTION............................................................................... 3 
2.1 PUBLIC HEALTH IMPACT OF THE AGING POPULATION .......................... 3 
2.2 DEFINITIONS OF AGING .......................................................................... 4 
2.3 THEORIES OF AGING ............................................................................... 5 
2.4 TELOMERE AND AGING ........................................................................... 6 
2.5 VASCULAR AGING .................................................................................. 7 
2.5.1 Arterial Anatomy................................................................................. 8 
2.5.2 Shear and Tensile Stress ..................................................................... 8 
2.5.3 Collagen & Elastin ............................................................................... 9 
2.5.4 Intima Media Thickening ................................................................. 10 
2.5.5 Blood Pressure Changes .................................................................. 10 
2.5.6 Reactive Oxygen Species (ROS) and Oxidative Stress ................ 12 
2.5.7 Nitric Oxide Production Changes ................................................... 12 
2.6 SUBCLINICAL CARDIOVASCULAR DISEASE MEASURES ....................... 13 
2.6.1 Common Carotid Artery Adventitial Diameter .............................. 13 
vii 
2.6.2 Common Carotid Artery Lumen Diameter ..................................... 14 
2.6.3 Common Carotid Artery Intima Media Thickness ......................... 14 
2.6.4 Carotid Plaque .................................................................................. 15 
2.6.5 Carotid-Femoral Pulse Wave Velocity............................................ 16 
2.7 LIFESTYLE FACTORS ................................................................................ 17 
2.7.1 Sleep and Obstructive Sleep Apnea .............................................. 17 
2.7.2 Physical Activity in Older Adults...................................................... 19 
3.0 THE EFFECTS OF HO RMONE THERAPY ON COMMON  CAROTID ARTERY  
ADVENTITIAL   DIAMETER IN EARLY POSTMENOPAUSAL WOMEN ............................. 22 
3.1 INTRODUCTION ...................................................................................... 23 
3.2 METHODS ............................................................................................... 25 
3.2.1 Study Population ............................................................................... 25 
3.2.2 Carotid Ultrasound Measures .......................................................... 26 
3.2.3 Visits ................................................................................................... 27 
3.2.4 Analytical Methods .......................................................................... 28 
3.3 RESULTS ................................................................................................... 30 
3.4 DISCUSSION ........................................................................................... 32 
3.5 ACKNOWLEDGEMENTS ......................................................................... 38 
3.6 SOURCES OF FUNDING ......................................................................... 38 
3.7 DISCLOSURES ......................................................................................... 38 
3.8 REFERENCES FOR CHAPTER 3 ................................................................ 39 
3.9 TABLES FOR CHAPTER 3 .........................................................................44 
viii 
4.0 ASSOCIATIONS OF  SLEE P QUALITY A ND SLEEP APNEA RISK  WITH 
SUBCLINICAL CARDIOVASCULAR DISEASE IN YOUNG ADULTS ................................ 48 
4.1 INTRODUCTION ...................................................................................... 49 
4.2 METHODS ............................................................................................... 51 
4.2.1 Study Population ............................................................................... 51 
4.2.2 Screening .......................................................................................... 52 
4.2.3 Laboratory Tests ................................................................................ 53 
4.2.4 Sleep Questionnaires ....................................................................... 53 
4.2.5 B-mode Ultrasound Measurements ................................................ 55 
4.2.6 Statistical Methods ............................................................................ 56 
4.3 RESULTS ................................................................................................... 58 
4.4 DISCUSSION ........................................................................................... 60 
4.5 ACKNOWLEDGEMENTS ......................................................................... 63 
4.6 FUNDING RESOURCES ........................................................................... 63 
4.7 DISCLOSURES ......................................................................................... 63 
4.8 REFERENCES FOR CHAPTER 4 ................................................................ 64 
4.9 TABLES FOR CHAPTER 4 ......................................................................... 69 
5.0 SUBCLINICAL ATHEROSC LEROSIS AND P HYSICAL ACTIVITY I N OLDER 
ADULTS: LIFE RANDOMIZED PILOT STUDY .................................................................... 73 
5.1 INTRODUCTION ...................................................................................... 74 
5.2 METHODS ............................................................................................... 76 
5.2.1 Population ......................................................................................... 76 
ix 
5.2.2 Screening, Baseline Assessment ..................................................... 77 
5.2.3 6-month Follow-up Assessment ...................................................... 78 
5.2.4 Ultrasound Measures ........................................................................ 79 
5.2.5 Intervention ....................................................................................... 80 
5.2.6 Statistical Methods ............................................................................ 81 
5.3 RESULTS ................................................................................................... 83 
5.4 DISCUSSION ........................................................................................... 85 
5.5 ACKNOWLEDGEMENTS ......................................................................... 91 
5.6 SOURCES OF FUNDING ......................................................................... 91 
5.7 DISCLOSURES ......................................................................................... 91 
5.8 REFERENCES FOR CHAPTER 5 ................................................................ 92 
5.9 TABLES AND FIGURES FOR CHAPTER 5 ................................................. 98 
6.0 GENERAL DISCUSSION ................................................................................ 104 
6.1 SUMMARY OF FINDINGS ..................................................................... 104 
6.2 PUBLIC HEALTH SIGNIFICANCE........................................................... 108 
6.3 FUTURE RESEARCH ............................................................................... 111 
6.4 REFERENCES FOR CHAPTER 6 .............................................................. 113 
BIBLIOGRAPHY ........................................................................................................... 115 
x 
 LIST OF TABLES 
Table 3.1 Baseline demographic, anthropometric and health characteristics of 
WOMAN cohort by HT use   ............................................................................................. 44
Table 3.2 Baseline subclinical measures of cardiovascular disease of WOMAN 
cohort by HT use   .............................................................................................................. 45
Table 3.3 Univariate linear regression showing the association of demographic & 
cardiovascular risk factors with common carotid artery adventitial diameter   .... 46
Table 3.4 Multivariable linear regression of factors associated with common 
carotid artery adventitial diameter   ............................................................................. 47
Table 4.1 Baseline demographic, anthropometric and health characteristics   .... 69
Table 4.2 Sleep and subclinical CVD characteristics by gender   ............................ 70
Table 4.3 Low risk and high risk for sleep apnea & subclinical CVD measures by 
gender   .............................................................................................................................. 71
Table 4.4 Snoring status & subclinical CVD measures by gender   ........................... 72
Table 5.1 Baseline characteristics of randomized groups   ........................................ 98
Table 5.2 Baseline, 6-month and change in subclinical measures by intervention 
group   ................................................................................................................................ 99
xi 
LIST OF FIGURES 
 
Figure 5.1 Box plot of change in pulse wave velocity by intervention group   ..... 100
Figure 5.2 Box plot of change in adventitial diameter by intervention group   .... 101
Figure 5.3 Box plot of change in lumen diameter by intervention group   ............ 102
Figure 5.4 Box plot of change in intima media thickness by intervention group   103
xii 
ACKNOWLEDGEMENTS 
 
My journey to become an Epidemiologist began with a middle school 
assignment to find three careers in science. The journey has been like a 
marathon; it has not been easy. However my grandfather prepared me with the 
words of Booker T. Washington, “Nothing ever comes to one, that is worth 
having, except as a result of hard work.”  Those wise words have encouraged, 
sustained and been a reminder challenges were merely part of the process.  I 
express my gratitude to those who came before me who made my journey a 
little less tough, to those who made sacrifices so that I could achieve my 
dreams, and to those who supported, encouraged, prayed and loved me all 
along the way.  
Dr. Sutton-Tyrrell you have been instrumental to my success.  Thank you for your 
support, kindness and faith. You saw my potential and helped me develop my 
skills, identify my strengths, improve upon my weaknesses, experience 
opportunities to grow personally and professionally, and you encouraged, and 
guided me to become a better scientist and a great researcher.   
xiii 
Drs. Newman and Cauley you believed in me and trained me in the area of 
aging. I thank you for your encouragement, faith, compassion, and wisdom.  I 
am grateful for the financial support of the NIA aging training grant. 
To my dissertation committee, I am a better epidemiologist because of your 
time, patience, wisdom, guidance and dedicated commitment to teaching 
and training me, many thanks to you.  
Dr. Emma Barinas-Mitchell I am grateful for your encouragement, your 
willingness to listen and to share your strategies to resolve research and life 
dilemmas.  I also thank the URL staff for the opportunity to volunteer and gain a 
better understanding of ultrasonography techniques. 
The research staff at the Bellefield clinic and everyone who worked on SAVE in 
the clinic, recruitment office, lab, data management, and ancillary studies I am 
grateful for your patience and training.  I especially thank Laura, Eileen, Alice, 
Mary Ellen, Marilyn and Judy for sharing their wisdom, being so understanding, 
kind and supportive and Drs. Conroy, Rice and Storti for sharing your expertise. 
The Aging and Cardiovascular Trainees, and the graduate students who resided 
in G3H between August 2005 and April 2010, have been a great support; I thank 
you for your time, wisdom and inspiration.  I am grateful for the friendships made 
during my grad school journey. Genevieve, Candace, Allison, Iva, Nora, Sheng- 
Chia and Danielle your support and understanding helped me overcome the 
xiv 
challenges of life as a graduate student.  We multiplied our joys and divided our 
sorrows; you each uniquely contributed to my life to make it better.  
I thank the Epidemiology Department and Chairs for the opportunity to speak to 
the new students in our department at orientation; it has truly been an honor.  
Drs. Mishoe, Cooper, Sorlie, Bookman, Cutler, Fine, Leifer, Obarzanek, Pratt, 
Simons-Morton, Ms. Nelson and all the brilliant individuals of NHLBI DECA (now 
DCS) Clinical Applications, Epidemiology and Biostatistics branches who trained 
and formally introduced me to epidemiology as a research fellow in the 
BRTPUG, I thank you.  
Dr. Black and Veebee (AlTrev) I appreciate your love, support and prayers 
throughout the process. You both embraced my dream & helped me reach it. 
I thank God for directing me to places where I could serve and honor Him and 
for His grace that kept me. My Mt. Vernon and Macedonia Church Families, I 
thank you for nurturing my spiritual well-being and teaching me to identify and 
use my gifts.  I especially thank Macedonia’s Women’s Sunday school class for 
their friendship, prayers and support and the New Disciples Ministry and Pastor 
Shalone for nurturing my gift for teaching.  
My lifelong “sisters” Natalie and Shayla, and my twin Kelly, thank you for always 
lending a listening ear, sharing words of wisdom, encouraging me when I was 
xv 
discouraged, and for the great memories we created when you visited 
Pittsburgh. 
I am so grateful for the unconditional love and support of my family. To my 
parents, thank you for teaching me the importance of faith, balance, discipline, 
and the simple things in life that give it value, meaning and purpose. You raised 
me to bravely pursue my dreams and never allow anyone to put limits on what I 
can achieve.  I am also thankful for your sacrifices. Kevin, you are an amazing 
brother who is always so thoughtful and wise, thank you for your 
encouragement and love.  Grandma Lemay you have been so supportive in so 
many ways thank you for your love, prayers, encouragement and your delicious 
brownies and pound cakes. I thank Sheldon & Margui and great uncle Dub 
(William) for reminding me the importance of laughter.  Thank you for your 
prayers, love, support and shelter, Renee. My great aunt Idenia and my cousins, 
I thank you for taking such good care of me while I’ve lived in Pittsburgh.  You 
helped me find housing, move in my apartment and made sure I was never 
home-sick during the holidays with your spectacular home cooked meals. 
My dear Jayson, we met just before I began graduate school so you have 
known me during the most challenging part of my life.  Through it all, the good, 
the bad, and the ugly you have been there to weather the storm with me.  You 
are an amazing person and I am so grateful to have your calm spirit, support, 
understanding and love during the journey.   
xvi 
To my late grandparents Lloyd, grandpa Lemay, great grandpa Peace and my 
great aunt Mary you were all very important to me; your presence in my life 
made my life so much richer!  I thank you for your love, encouragement, faith, 
wisdom and legacy.  
1 
1.0  DISSERTATION OVERVIEW AND OBJECTIVE 
 
The purpose of this dissertation is to evaluate the effect of lifestyle factors on the 
vascular aging process measured by B-mode ultrasound in three cohorts 
spanning the life course.  The following questions are addressed in the three 
papers that are included in this dissertation: 
 
1. The cardiovascular benefit of hormone therapy in postmenopausal 
women has been controversial.   Studies of cardiovascular events and 
subclinical cardiovascular disease have provided information to better 
understand that benefit may be limited to women with certain vascular 
characteristics. The purpose of paper one was to determine if there were 
differences in adventitial diameter in postmenopausal women currently 
taking hormone therapy compared to those not currently taking hormone 
therapy in the Women on the Move through Activity and Nutrition study. 
 
2. Sleep related breathing disorders have been linked to cardiovascular 
disease and its risk factors.  The majority of research on sleep apnea has 
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been in children, adolescents, middle and older adults; few studies have 
assessed young adults between 20 and 45 years.  The goal of paper two 
was to determine whether sleep quality and sleep apnea risk were 
associated with aortic pulse wave velocity, common carotid artery intima 
media thickness, adventitial diameter and lumen diameter in young 
adults at the baseline assessment of the Slow Adverse Vascular Effects of 
obesity (SAVE) randomized trial. 
 
3. Physical activity has been shown to be beneficial to the vasculature of 
young and middle-aged adults.  Studies evaluating the benefits of 
physical activity on subclinical cardiovascular disease measures in older 
adults > 70 years old have been limited.  The objective of paper three was 
to determine if progression of aortic stiffness, measured by pulse wave 
velocity, and arterial changes measured by common carotid artery intima 
media thickness, adventitial diameter and lumen diameter differ in 
sedentary older adults after a 6-month moderate physical activity 
intervention compared to an education-only control group in an ancillary 
study of the Lifestyle Interventions and Independence for Elders pilot trial. 
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2.0  GENERAL INTRODUCTION 
“Old age is not a phase of decline and loss, but instead, if approached 
properly, harbours the opportunity for positive change and productive 
functioning.” – Cicero1 
2.1 PUBLIC HEALTH IMPACT OF THE AGING POPULATION 
The American older adult population (defined as > 65 years old) is expected to 
grow from 36.5 million in 2002 to 71.5 million by 2030; this new demographic will 
make up ~20% of the United States population2. Declining birth rates, longer life 
expectancy and the aging baby boomer generation will all contribute to the 
changing population distribution3.  Health care costs which accounted for 16% 
of the United States Gross Domestic Product in 2008 are also expected to grow4. 
 
Thus, prevention or delay of chronic diseases like stroke, the leading cause of 
long-term disability5, and maintenance of independent living for as long as 
possible will be even more important for the country’s economic resources.   
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2.2 DEFINITIONS OF AGING 
Aging is a natural phenomenon beginning at conception and continuing as the 
organism matures until death.  There are different ways to classify age in 
humans: chronological, biological, societal and subjectively as successful or 
unsuccessful6.  Chronological age is the most commonly used definition referring 
to the amount of time since birth6. This definition presumes that the rate of aging 
in all humans is identical7. Chronological age has been a long standing 
traditional risk factor for cardiovascular disease.  Biological age is the presence 
or absence of pathological processes6. Unlike chronological aging, biological 
aging is unique to each individual and is influenced by evolution and genetics, 
natural selection7, and environmental exposures. It has been recommended 
that age be defined based on normal aging that is universal, degenerative, 
progressive and intrinsic6.  This definition should differentiate aging from normal 
processes of growth and development6. Societal age is linked to social norms of 
what is appropriate for people of different chronological age6. Successful aging 
is a concept captured in Cicero’s quote; it is characterized by prevention or 
delay of chronic disease, morbidity and disability6. Positive changes and 
productive functioning can be the ability to learn new skills and use new 
technologies that can counteract declines in some activities of daily living.  They 
can also be practicing preventative measures (i.e. eating a balanced diet, 
participating in physical activity) to delay or slow the progression of disease.  
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2.3 THEORIES OF AGING 
The rate of age-associated changes varies based upon many factors including 
those that are environmental, genetic and a blend of the two6. There are 
several theories of how and why aging occurs that take these factors into 
account6, 8.  Two longstanding theories with support from animal and human 
studies are the rate-of-living hypothesis and free radical theory9. They are now 
combined to explain the complex process of aging. The rate-of-living hypothesis 
is based upon the premise that an organism’s metabolic rate is linked to its life 
expectancy. This theory was based on observations that most organisms with a 
higher metabolic rate had shorter life spans than those with lower metabolic 
rates10, 11.  Exceptions to this are observed in primates and birds who live 
considerably longer than predicted10, 11. The free radical theory of aging states 
that chronic oxidative stress in an organism yields oxidative end products10, 12 
also known as reactive oxygen species (ROS) that cause cellular damage to the 
body13.  ROS effect biological tissues in the same way although the response to 
cumulative damage is different based on the type of cell7. ROS are known to 
accelerate telomere attrition leading to accelerated cell senescence. 
Senescence occurs when a cell can no longer replicate14.  The combination of 
the rate-of-living and free radical theories postulates that a higher metabolic 
rate produces more ROS; thus, contributing to a shorter life span10. 
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2.4 TELOMERE AND AGING 
Like the caps on the end of shoe laces, telomere are specialized DNA-protein 
complexes at the end of eukaryotic chromosomes15 that preserve genome 
integrity and stability16, 17.  Telomere shorten with each cell division in somatic 
cells18.  As a result, studies have shown biologically older organisms have shorter 
telomere than younger ones in animal models11 and in humans19. The rate of 
telomere shortening is influenced by genetic and environmental factors20. 
Telomere length has X-linked inheritance21.  Consequently, telomere length is 
largely heterogeneous between individuals, and cells types within individuals19.  
Although there are no differences in telomere length in newborn males and 
females22 in adulthood females have longer telomere than age-matched males 
21, 23-27 which may be a result of slower biological aging in females.  These 
differences may also be related to estrogen that will be further discussed in 
Chapter 3.  Individuals with premature/accelerated aging syndromes (i.e. 
Werner syndrome, ataxia telangectasia, dyskeratosis congenita) show 
accelerated telomere shortening compared to individuals without these 
conditions28. Cross-sectional and cell culture studies have shown some 
traditional cardiovascular risk factors are associated with shorter telomere length 
including hypertension29, diabetes30, dyslipidemia, homocysteine31, 32, obesity33-
36, smoking33, 35, and response to stress37. Cross-sectional studies of individuals 
with a greater burden of subclinical cardiovascular disease27, 33, those with 
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cardiovascular disease38, 39, and those with cerebrovascular disease40 also have 
shorter telomeres.  These findings support evidence that cardiovascular risk 
factors and disease reflect accelerated vascular aging. 
2.5 VASCULAR AGING 
Vascular aging, or age-associated changes that occur throughout the blood 
vessels of the arterial tree, is characterized by many physiological changes.  
These changes affect genetic and functional responses in the body. The rate of 
vascular aging is likely influenced by underlying physiological alterations 
resulting from arterial pulse pressure widening, hypertension, dyslipidemia, 
diabetes, genetic factors41, inactivity, and obesity.  Some of these vascular age-
related changes are reduced compliance, increased inflammatory response42, 
increase in vascular smooth muscle cells, impaired angiogenesis43, 44, reduced 
anti-thrombogenic property of the endothelium45, thickening of the intima 
media, dilation of the lumen 46 and increased adventitial diameter.   
Atherosclerosis is a disease of the arteries that begins as a fatty cholesterol 
streak in the inner wall of the artery; regression or further development is 
dependent upon several factors. Atherosclerosis in young adults may reflect 
accelerated aging of the vascular wall41, 47 indications of this process are arterial 
stiffening and increased adventitial diameter. 
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2.5.1 Arterial Anatomy 
The arteries are composed of three layers: the adventitia, the media and the 
intima.  The media layer is sandwiched between the external elastic lamina at 
the adventitia-media boundary and the internal elastic lamina at the media-
intima boundary48.  Each arterial layer has a distinct purpose, thus is composed 
of different cell types with varying densities.  The adventitia is the outermost layer 
of the artery; it is composed of mainly fibroblasts, collagen, and elastin fibers 
aligned longitudinally; mast cells, macrophages and ganglion cells can also be 
found in the adventitia48. Its composition provides structure to the artery and is 
critical for homeostasis of the vessel wall49.  The media, the middle layer of the 
artery, is made of layers of smooth muscle cells48 that provide stability and 
resiliency50.  The intima is the inner most layer of the artery; it is a single layer of 
intertwined endothelial cells48 attached to a thin extracellular matrix49.  The main 
purpose of the endothelium in arteries is to separate the circulating blood 
compartment from the tissue of the vascular wall49. 
2.5.2 Shear and Tensile Stress 
The blood vessel adapts to environmental changes through structural and 
functional changes. This adaptation is driven by two hemodynamic processes: 
shear and tensile stress50.  Shear stress is the tangential, mechanical force  
exerted on the vessel from the flow of blood; tensile stress is the force 
9 
perpendicular to the wall of the artery pushing outward on the inner artery 
wall50.  Shear stress is affected by changes in blood pressure and tensile stress is 
affected by changes in wall tension and wall thickness.  Optimal homeostatic 
conditions are met at a specific, constant level of shear and tensile stress.  Many 
of the vascular changes associated with aging—vascular stiffening, intima 
media thickening and enlarged adventitial diameter—disrupt the balance of 
shear and tensile stress. 
2.5.3 Collagen & Elastin 
Collagen and elastin are very important components of the arterial wall.  They 
are basic components of the adventitia, the outermost layer of the blood vessel.  
Collagen fibrils provide structure to the artery wall matrix, bearing the majority of 
tensile stress, and preventing excess distension51.  The elastin network provides 
tensile stress support, elasticity, resiliency, and allows the artery to respond to 
stress exerted by hemodynamic conditions by distributing stress evenly 
throughout the wall by dilation, constriction and absorption50. The quality54 of 
elastin in the artery walls declines with age52 as a result of inadequate 
production and increased fragmentation and fracture46. The increased 
collagen content interacts with free amino groups and forms advanced 
glycation end products that increase cross-linking46.  Increased cross-linking of 
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collagen and decreased quality and function of elastin causes increased 
arterial stiffness reflected by higher pulse wave velocity53.  
2.5.4 Intima Media Thickening 
The intima and media thicken with age. These changes are reflected in intima 
media thickness(IMT) which is strongly correlated with intrinsic arterial aging41. 
Several studies have shown thicker IMT in older participants compared to 
younger ones.  There is a doubling or tripling of IMT in people between the ages 
of 20 and 9054. Rodent55 and nonhuman primate56 models of aging reflect a 
thicker intima in older animals than in younger ones.  The animal models both 
observe intima medial thickening in the absence of atherosclerosis55, 56 
suggesting that intima medial thickening is part of the normal aging process.  
Normal thickening is characterized by smooth muscle cell hypertrophy57.  
2.5.5 Blood Pressure Changes 
The vascular system or arterial tree has two essential functions: 1. deliver blood 
from the left ventricle to capillaries of the organs and tissues that need it, and 2. 
cushion the pulsatile energy from the blood flow so that it is continuous58, 59.  
Aging vasculature is associated with reduced compliance, distensibility60, 61, 
baroreflex response60, 62, cardiac output while supine at rest60, 63, 64, and 
increased sensitivity to salt or sodium65; these factors all contribute to changes in 
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blood pressure.  Blood pressure has two components: a pulsatile component 
represented as systolic blood pressure (SBP) and a steady state component 
represented as diastolic blood pressure (DBP).  Arterial pressure is a balance 
between peripheral resistance, known to increase SBP & DBP, and central artery 
stiffness, known to increase SBP and lower DBP41. In young adults blood pressure 
is driven more by peripheral resistance, while blood pressure in older adults is 
driven by central artery stiffness explaining the increase in SBP and decrease in 
DBP observed in older adults (isolated systolic hypertension) and the increase in 
both in younger adults58, 66.   
 
Isolated systolic hypertension is elevation of brachial systolic blood pressure 
when diastolic blood pressure is normal or below normal and pulse pressure is 
elevated67.  Isolated systolic hypertension is most prevalent in adults over 60 
years of age67, 68; it effects 15% of adults over 6069.  Arterial stiffening is the main 
contributing factor of isolated systolic hypertension67, 68, 70.  This stiffening is 
directly related to changes in elastin, collagen, and nitric oxide production. 
Other contributing factors are increased stroke volume, diminished capacity of 
the aortic valve and arteriovenous shunts67.  Increased mortality and stroke were 
associated with isolated systolic hypertension in a meta analysis of 8 trials of 
isolated systolic hypertension patients >60 years old(n=15693)71. Treatment of 
isolated systolic hypertension lowered total mortality by 13%, cardiovascular 
mortality by 18%, cardiovascular complications by 26% and stroke by 30%71. 
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Obesity, smoking and low educational attainment appear to contribute to the 
phenomenon of isolated systolic hypertension in young adults under 40 years old 
from the National Health and Nutrition Examination Survey72. 
2.5.6 Reactive Oxygen Species (ROS) and Oxidative Stress  
Reactive Oxygen Species (ROS) are known to accelerate telomere attrition in 
vascular smooth muscle cells31, 73 leading to accelerated senescence.  The 
senescence of vascular endothelial cells may lead to endothelial dysfunction 
especially in areas susceptible to or with already developed atherosclerotic 
damage74.  Oxidative stress is a physiological state when there are more ROS 
than can be broken down by the cellular environment75, 76  
2.5.7 Nitric Oxide Production Changes 
Nitric oxide (NO) plays a critical role in the vascular system, especially in the 
endothelium.  NO is a potent vasodilator, produced in the endothelium as the 
response to antagonists and shear stress77.  NO can act as both an antioxidant 
and a pro-oxidant. Its role is determined by the chemical78 and physiological 
environment79.   As an antioxidant it is necessary for providing protection against 
leukocyte adhesion, thrombocyte aggregation, and smooth muscle cell 
proliferation80. Vessels in older organisms in different vascular beds in animal and 
human models81 show reduced response to NO-dependent vasodilator 
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response to acetylcholine82, and when hyperlipidemia, hypertension, or 
diabetes is present79.  These risk factors also slow NO synthesis and quicken 
destruction of the molecule77.  Aging is associated with diminished sensitivity to 
β2-adrenoceptor agonists leading to impaired vasoconstrictor response83. 
2.6 SUBCLINICAL CARDIOVASCULAR DISEASE MEASURES 
Subclinical cardiovascular disease, early signs of cardiovascular disease before 
symptoms or an event, can be measured using non-invasive, B-mode 
ultrasonography.  These measures are used in this dissertation and are described 
below. 
2.6.1 Common Carotid Artery Adventitial Diameter 
Adventitial diameter (AD), also referred to as inter-adventitial diameter in the 
literature, is a non-invasive measure of vascular health.  AD can be measured at 
different arterial sites; this document will refer to AD measured in the common 
carotid artery unless otherwise specified.  It is defined as the distance from the 
adventitial-medial interface on the near wall to the medial-adventitial interfaces 
on the far wall.  AD has been overlooked as a measure of interest because it 
was thought that lumen diameter was the measure that provided the most 
important information about vascular remodeling48.  This is true for the coronary 
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arteries but not for carotid arteries, the focus of this dissertation.  AD is 
reproducible and reliable84, 85.  AD is associated with several traditional 
cardiovascular risk factors and cardiovascular disease.  Larger adventitial 
diameters are associated with aging86-88, male gender89, 90, higher blood 
pressure84, 89, 90, glucose90, insulin, waist circumference, body mass index85, 86, 
lipids90, increased atherosclerotic lesions91 and plaques88, pre-existing coronary 
heart disease86, 92, 93 and prevalent cardiovascular disease 92-95. 
2.6.2 Common Carotid Artery Lumen Diameter 
Lumen, luminal or inner diameter is a non-invasive measure of the artery often 
paired with and strongly correlated with intima-media thickness.  It is a 
reproducible and reliable measure84, 96. Lumen diameter (LD) is larger in men 
than in women89, 90, 96-98 and is positively correlated with older age97, higher SBP96, 
mean arterial pressure98, body mass index (BMI)96, 98, cholesterol, apo-B96, pre-
existing coronary disease92 and intima media thickness. 
2.6.3 Common Carotid Artery Intima Media Thickness 
Intima media thickness (IMT) is one of the most commonly used subclinical B-
mode ultrasound measures used. It is measured as the distance between the 
lumen-intimal interface and the medial-adventitial interface. The measurement 
varies depending on whether both the left and right side, or one side is imaged, 
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the segment(s) of the artery used (common carotid, internal carotid, bulb), 
whether near and far wall images are used, and if plaque is included in the 
measurement.  IMT is typically the average of all segments and sides available.  
It is thicker in men than age matched women90.  IMT is reliable, reproducible99 
and measured in a wide variety of populations in several large epidemiological 
studies89, 100-105.  These studies have demonstrated the relationship between 
thicker IMT and traditional cardiovascular risk factors like age104, smoking100, 103, 
104, hypertension100, higher low density lipoprotein (LDL) cholesterol 100, 104 ; they 
have also shown that thicker IMT predicts pre-existing coronary heart disease92, 
coronary heart disease101, stroke102, and myocardial infarction102, 105. 
2.6.4 Carotid Plaque 
Carotid plaque is an indicator of atherosclerosis and predictor of myocardial 
infarction106, 107 and cardiovascular mortality107.  Carotid plaque can be 
assessed using B-mode ultrasound imaging.  In this dissertation it is defined as a 
distinct area protruding into the vessel lumen that is at least 50% thicker than the 
adjacent IMT. The degree of plaque is graded between 0 and 3 for each 
segment. A grade of zero is defined as no visible plaque.  A grade of one was 
defined as one small plaque that is less than 30% of the vessel diameter. A 
grade of two is defined as one medium plaque that is 30-50% of the vessel 
diameter or multiple small plaques.  A grade of 3 is defined as a large plaque 
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that is greater than 50% of the vessel diameter or multiple plaques with at least 
one medium plaque.  The plaque variable used was dichotomized as no plaque 
or any plaque. 
2.6.5 Carotid-Femoral Pulse Wave Velocity 
Increased pulse wave velocity (PWV) with age is observed even in populations 
with little or no atherosclerosis108.  Therefore, stiffening is not a definite indicator 
of atherosclerosis in all situations. It can be a characteristic of natural aging.  
Carotid-femoral PWV (cf-PWV), also known as central or aortic PWV, is a 
reproducible and reliable109, 110, non-invasive measure of arterial stiffness.  The 
pulsatile flow of blood creates a pressure waveform that carries energy from the 
heart throughout the arterial tree is reflected.  Cf-PWV is calculated as the 
distance the pulse wave travels from the carotid artery to the femoral artery 
divided by the time it takes the wave to travel this distance.  A higher PWV 
reflects a stiffer vessel and increased cardiovascular risk factors and events than 
a lower PWV.  Higher cf-PWV is associated with older age104, 111, 112, sedentary 
lifestyle112, higher blood pressure113, central adiposity114, diabetes115, and is a 
predictor of hypertension113, coronary heart disease116-118, stroke116, 118, 
cardiovascular mortality115, 117-120 and all-cause mortality115, 120. 
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2.7 LIFESTYLE FACTORS 
2.7.1 Sleep and Obstructive Sleep Apnea 
Sleep is essential for health, wellbeing and the ability to function at our best.  It is 
not a passive activity; during sleep the body repairs and regenerates tissues, 
builds bone and muscle, and secretes hormones. This is accomplished during  
two sleep cycles, rapid eye movement (REM) and non-rapid eye movement 
(non-REM),  and 5 stages of sleep121.  Approximately 50% of sleep in children is 
REM sleep122,122 compared to 20% in adults and declines with age121.  The 
average adult needs 7-8 hours of sleep daily; < 6 hours of sleep or > 8 hours of 
sleep have been indicative of higher risk of all-cause mortality123.  Data from two 
cohort studies of men and women from the United States and the United 
Kingdom found that short sleep duration (<6 hours) was correlated to obesity 
and poor health, while long sleep duration (>8 hours) was associated with 
comorbidities124. 
 
Sleep apnea (SA) is disordered breathing caused by repeated episodes of 
reduced air flow (hypopnea) and complete cessation of air flow (apnea) 
caused by collapse of the pharyngeal airway during sleep.  The severity of SA is 
determined by the number of apneas and hypopneas per hour of sleep or the 
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Apnea Hypopnea Index (AHI)125-127.  Mild SA is defined as an AHI of 5-14, 
moderate an AHI 15-29 and severe an AHI 30 or greater126.   
 
Obstructive Sleep Apnea (OSA) is the most common type of SA with an 
estimated prevalence of 24% in men and 9% in women 30-60 years old in the 
United States128 but is usually undiagnosed126, 129. OSA is most strongly linked to 
obesity130, 131, male gender132 and age127, 132. It is also associated with 
hypertension133, 134, diabetes and insulin resistance 134, 135, higher PWV136 and 
IMT136, 137 compared to controls and less severe OSA participants. There is a great 
deal of literature on OSA in children and middle and older adults but there is 
gap in the literature on OSA in young adults 18-30 years old138.  Possible reasons 
could be OSA is not thought to be a disease of young adults because they 
often do not report symptoms. Laboratory polysomnography is the gold 
standard for sleep evaluation and diagnosis of SA although its use in 
epidemiological studies are limited due to the time-consumption of the test, 
participant burden, and expense of the equipment and reading the data139.  As 
a result portable home monitors140 and questionnaires141 have been developed 
as effective measures to determine those at risk for SA.   
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2.7.2 Physical Activity in Older Adults 
Physical activity elicits beneficial changes in the cardiovascular system and in 
some cardiovascular risk factors.  Results of intervention studies show increased 
physical activity lowers CV risk142-145.  Brisk walking has been shown to reduce the 
risk of CV events144, blood pressure143, myocardial infarction145 and coronary 
heart disease142. Physical activity is thought to slow the progression of 
atherosclerosis by effecting weight, blood pressure, insulin sensitivity, glycemic 
control, lipid profile, fibrinolysis, endothelial function and inflammatory response 
systems146.  These changes slow the deterioration of function and health 
observed with aging, even in older adults in observational studies and short 
duration clinical trials 147.  However, the duration and intensity of physical activity 
required to produce clinically meaningful improvements in the vasculature of 
older adults is unknown.   
 
Compliance reflects how well and artery responds to changes in pressure and 
volume by expanding and recoiling.  Compliance is reduced with age as 
arteries lose their elasticity and volume change is reduced. Aerobic activity 
improves arterial compliance in middle-aged and older adults148-150 without 
isolated systolic hypertension151. 
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To date, the evidence of physical activity’s effect on arterial stiffness, measure 
by PWV is inconclusive. Two cross-sectional studies of physically active 
endurance trained older men from the Baltimore Longitudinal Study of Aging150 
and endurance trained postmenopausal women152 found the endurance 
trained individuals had less arterial stiffness, measured by PWV, than their 
sedentary age-matched peers. However, two randomized studies of adults with 
elevated blood pressure (an eight week cross-over cycling or sedentary lifestyle 
intervention in men,151  and a three month walking intervention versus sodium 
restriction control group in postmenopausal women153) did not find differences 
in change in arterial stiffness, also measured by PWV, between active and 
sedentary groups151, 153.  The short duration of the interventions (< 3 months), the 
study populations and the comparison group in the case of the latter study, may 
explain the findings.  High blood pressure may slow the positive effects of 
physical activity151, 153, thus requiring a longer duration of activity before benefit 
is observed. Additionally, the postmenopausal women in the sodium restriction 
control group had a large reduction in arterial stiffness152. Consequently, the 
effect of physical activity was not compared to sedentary behavior alone.  
 
The evidence of physical activity’s effect on intima media thickness is also 
inconclusive. A cross-sectional study of physical activity level assessed by 
questionnaire did not find a significant trend in IMT across the three groups of 
activity level in a cohort of men and women 65 and older154.  Another cross-
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sectional study that compared sedentary and endurance trained adults also 
found no relationship between activity and IMT154, 155.  A third cross-sectional 
study found that active adults who ate a healthy diet had lower IMT than 
sedentary adults who ate an unhealthy diet156.  However, this relationship was 
only present in non smokers; diet and activity were not examined separately in 
this study156. Finally, a longitudinal study observed slower progression rates of IMT 
in active peri- and postmenopausal women compared to the sedentary age-
matched peers157.    
 
To better understand the effects of physical activity on the vasculature of older 
adults a randomized physical activity intervention of longer than three months is 
needed.   
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3.1 INTRODUCTION 
Observational studies of hormone therapy (HT) have consistently suggested a 
cardiovascular (CV) benefit of estrogen1, while clinical trials have shown an 
increase in CV events among women randomized to HT use2, 3.   Recent animal 
data, as well as observational and clinical studies suggest that in 
postmenopausal women, the effects of estrogen on the vasculature may vary 
by age, years since menopause, degree of atherosclerosis at time of therapy 
initiation4-8, method of administration and composition (estrogen versus estrogen 
and progesterone).  Possible benefits of HT on subclinical CV disease have been 
observed in randomized studies of younger women evaluating coronary artery 
calcium9 and common carotid artery (CCA) intima media thickness (IMT)10, 11.  
Postmenopausal women, aged 50-59 years, who had undergone hysterectomy 
and were on estrogen only HT had 30-40% less coronary artery calcium than 
those randomized to placebo; these results were robust in adjusted and 
unadjusted models9.  Long term (> 2 years) HT use in postmenopausal women 
diminished age associated changes in IMT; short-term use and non-use did not10, 
11.   
 
Despite wide use of HT, the direct effect of hormones (endogenous or 
exogenous) on the vasculature in humans is not completely understood.  Recent 
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data from the Study of Women’s Health Across the Nation (SWAN) suggest that 
declining endogenous estrogen with the menopausal transition has a direct 
effect on the peripheral vasculature12.  Lower levels of estradiol were 
significantly associated with larger CCA adventitial diameters (AD) even after 
adjustment for CV risk factors12.   
  
Larger adventitial diameters are associated with aging13, 14, CV risk factors 12, 15-
17, and prevalent cardiovascular disease18-21.   Thus, the increase in AD observed 
with declining endogenous estrogen12 suggests that lower levels of endogenous 
estrogens are associated with a less healthy vasculature.  The strong association 
between AD and endogenous estrogen suggests a similar association may exist 
with the use of exogenous estrogen. The purpose of this study is to determine 
whether early postmenopausal HT users have significantly different AD than 
those who were not current users of HT in the Women on the Move through 
Activity and Nutrition (WOMAN). 
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3.2 METHODS 
3.2.1 Study Population 
The WOMAN study is a randomized clinical trial testing the ability of non-
pharmacological lifestyle intervention to modify CV risk factors in 
postmenopausal women22.  The study recruited 508 eligible African American 
and Caucasian women from Allegheny County, Pennsylvania between April 
2002 and October 2003 through direct mailings.  Briefly, eligible women were 
postmenopausal, between 52 and 62 years of age, able to walk, currently using 
HT, willing to participate in either intervention group regardless of assignment 
and had a waist circumference of >80 cm, a body mass index (BMI) between 
25.0 and 39.9 kg/m2, blood pressure < 160/95 mmHg, and low density lipoprotein 
(LDL) cholesterol between 100 and 160 mg/dL.  Women were ineligible if they 
were taking medication for cholesterol, diagnosed with or on medication for 
diabetes, diagnosed with a psychotic disorder, or suffering from depression22.  
Written informed consent was obtained from all the participants.  The study was 
approved by the University of Pittsburgh’s Institutional Review Board. The results 
of the WHI estrogen/progestin arm were published in the middle of recruitment3; 
as a result the eligibility criterion of current use of HT was modified to current or 
recent history of hormone use22.  Recent history of hormone use was defined as 
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prior use of at least 2 years within 6 months of randomization.  The decision to 
remain on HT was determined by the participant and her physician.  At baseline, 
40% of the women had discontinued use of HT (these women will be referred to 
as HT non users) and 60% remained on HT (these women will be referred to as HT 
users).  The effects of HT diminish quickly after use is discontinued. The primary 
endpoints of the study were coronary artery calcium, pulse wave velocity and 
CCA IMT.   
3.2.2 Carotid Ultrasound Measures 
CCA IMT, AD, lumen diameter (LD) and plaque were assessed by B-mode 
ultrasound using the Toshiba SSA-270A duplex scanner (Toshiba American 
Medical Systems, Tustin, CA) with a 5-MHz linear array transducer.  Right and left 
carotid images were taken of the near and far walls of the distal common 
carotid artery 1 cm proximal to the carotid bulb22.  IMT was defined as the 
distance from the lumen-intimal interface to the medial-adventitial interface.  
AD was defined as the distance from the adventitial-medial interface on the 
near wall to the medial-adventitial interface on the far wall.  LD was defined as 
the distance from the intima-lumen interface of the near wall to the lumen-
intima interface of the far wall.  The interfaces were traced electronically over 
the distal CCA and a computer generated measurement was obtained for 
27 
each pixel in the area of interest; these measurements were averaged to 
determine the IMT, AD, LD used for this analysis. 
 
Plaque was determined based on grading each of the 5 segments of the left 
and right carotid artery (distal and proximal CCA, carotid bulb, and proximal 
internal and external carotid artery).  Plaque was defined as a distinct area 
protruding into the vessel lumen that was at least 50% thicker than the adjacent 
IMT. For each segment the degree of plaque was graded between 0 and 3. A 
grade of zero was defined as no visible plaque.  A grade of one was defined as 
one small plaque that was less than 30% of the vessel diameter. A grade of two 
was defined as one medium plaque that was 30-50% of the vessel diameter or 
multiple small plaques.  A grade of 3 was defined as a large plaque that was 
greater than 50% of the vessel diameter or multiple plaques with at least one 
medium plaque.  Plaque was dichotomized into no plaque or any plaque. 
3.2.3 Visits 
The first of two pre-randomization screening visits included a 12-hour fasting 
blood draw, physical measures of height, weight, waist circumference, blood 
pressure, the long distance corridor walk, medical, physical activity and weight 
history.  Conventional enzymatic methods were used to obtain total cholesterol, 
high density lipoprotein (HDL) cholesterol and triglyceride concentrations from 
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the blood samples22.  LDL cholesterol was estimated using the Friedewald 
equation22.  Medical history included history of drug, vitamin/mineral 
supplement, and alcohol use22.  CCA AD, LD, IMT and plaque were measured at 
the second screening visit22. 
3.2.4 Analytical Methods 
Five hundred eight women were randomized into the WOMAN study.  
Seventeen women had incomplete data for the calculation of AD or IMT and 
were excluded from this analysis leaving a final sample size of 491 women.  All 
analyses were completed using SAS v9.1 (SAS Institute Inc., Cary, NC). A p-value 
< 0.05 was considered statistically significant.   
 
Descriptive statistics and normality of continuous measures were assessed for the 
cohort. Differences in demographic, anthropometric and health characteristics 
between the users and non users were determined using chi-square analyses for 
categorical variables and either t-tests or Wilcoxon-rank sum tests for continuous 
variables.   
 
Simple linear regression was used to assess univariate associations between AD 
and HT use and AD with the following CV risk factors:  age, race, systolic and 
diastolic blood pressure, pulse pressure, BMI, weight, height, waist 
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circumference, total, LDL and HDL cholesterol, triglycerides, glucose, insulin, 
smoking and antihypertensive medication use.  Multivariable linear regression 
was used to test for the following predetermined covariates: age, race, pulse 
pressure, and smoking status and any significant variable in the univariate 
analysis. The predetermined covariates were selected based on their 
association with AD in other studies. When collinearity was suspected(r > 0.4), 
Spearman correlations between the variables were determined and the 
variable most strongly correlated to AD was selected for the analysis.  Pulse 
pressure was chosen over systolic blood pressure, weight over waist 
circumference and BMI, and glucose over insulin for the multivariable model.  
The most parsimonious model was chosen. 
 
 
30 
3.3 RESULTS 
The mean age of the women was 57 ± 3.0 years, mean BMI was 41.2 ± 3.8 kg/m2; 
11% were African American and 6% were current smokers. There were 197 HT 
non users and 294 HT users at the time of the baseline carotid ultrasound scan.  
HT non users were older and had a higher percentage of African Americans. 
Overall HT non users had a significantly worse CV disease risk profile than HT 
users: higher total cholesterol, LDL cholesterol, glucose and insulin and lower HDL 
cholesterol (Table 3.1).  There were, however, no statistically significant 
differences in blood pressure, measures of general or central obesity, and 
smoking status by HT status (Table 3.1). 
 
The AD and LD were larger in the HT non users than in the users (p = 0.0013, p = 
0.0024, respectively, Table 3.2). However, IMT and presence of plaque were 
similar between the two groups (Table 3.2).   
 
Simple linear regression showed that AD was smaller in HT users, AD was 
significantly positively associated with SBP, pulse pressure, BMI, weight, height, 
waist circumference (all p <0.001), glucose, insulin (all p=0.01) and use of 
antihypertensive medications, and negatively associated with African American 
race, and cigarette smoking and (p<0.05) (Table 3.3).  HT use, African American 
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race and cigarette smoking were associated with smaller AD.  All of the other 
risk factors were positively associated with AD.  
 
The final multivariate model forced age, race, pulse pressure, and smoking 
status as covariates (Table 3.4). The model was also run controlling for anti-
hypertensive medication use, but this variable fell out of the multivariable model 
when pulse pressure was added. HT non-use, higher pulse pressure, and higher 
weight were significantly associated with larger AD (all p < 0.01, Table 3.4).  HT 
use was associated with a 0.16 mm smaller AD. Current cigarette smokers had 
0.18 mm smaller AD than current non-smokers, with borderline significance 
(Table 3.4).  Age, race and smoking status were not statistically significant in the 
final model. 
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3.4 DISCUSSION 
Early postmenopausal HT users had significantly smaller AD than HT non users.  
This relationship remained after adjustment for known CV risk factors.  The HT 
users also had significantly smaller LD than the non users.  This is clear evidence 
that HT is associated with vascular geometry in early postmenopausal women.  
 
The current study found that exogenous estrogen has similar associations with 
AD as endogenous estrogen as seen in the SWAN Heart study12; smaller AD was 
associated with higher levels of estrogen.  LD was also significantly smaller in the 
HT group in the current study. Similar results were found in this study in a cross-
sectional study of non-oral (percutaneous gel or transdermal patch) HT. HT users 
had smaller LD than non-users11 which is consistent with these findings.  Together, 
these findings suggest the positive effect of estrogen on the vasculature may be 
through maintenance of vascular structure and function. The adventitia, the 
outer most layer of the artery, is composed of supportive connective tissue, 
fibroblasts, collagen, and elastin fibers23. Estrogen is known to preserve arterial 
structure by slowing elastin and connective tissue degradation, and slowing 
age- and estrogen-related increases in collagen that increase vascular 
stiffening24. A small diameter reflects a healthy vasculature that is able to 
maintain an optimal balance of shear and tensile stress25-27. An enlarged 
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diameter is unable to effectively control levels of shear stress.  This can make the 
artery vulnerable to injury and atherosclerotic development17, 23. The current 
study and the SWAN Heart study found that larger AD was associated with older 
age, higher systolic blood pressure, higher glucose and higher insulin: all risk 
factors for CVD. Additional supporting evidence that enlarged diameter is an 
indicator of poor vascular health come from several studies showing enlarged 
AD is associated with CV disease risk factors12, 13, 17, increased IMT20, plaque20, 28, 
and acute coronary events20.   
 
Arterial diameter enlargement precedes intimal thickening and may explain 
why arterial diameter differences in HT users and non users were observed in this 
study but differences in IMT were not.  These findings contribute to the mixed 
findings of prior studies of HT and IMT10, 11, 19, 29-33.  Prior studies have been of 
American19, 30, Australian32, French11, 31, German29, and Japanese10, 33 women, 
undergoing diverse types of HT regimens. The variability in study design 
complicates the ability to draw conclusions.  There is evidence that the human 
response to ovary-produced 17β-estardiol and estrone is different than the 
response to equine derived conjugated equine estrogen34. This is due to equine 
estrogens that are not found in humans and their affinity to the estrogen 
receptors compared to the other forms of estrogen34. In addition, the route of 
estrogen therapy affects the physiological response of the body.  Transdermal 
therapy bypasses processing through the liver resulting in no adverse increase in 
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triglyceride35, or C-reactive protein36 seen when oral therapy is used.  This may 
explain why both studies of transdermal therapy found IMT and IMT progression 
to be significantly different in HT users and non HT users11,33. HT users had 
significantly thinner IMT than non-users in the cross-sectional study11; HT users had 
significant reductions in IMT progression after a year compared to non-users in 
the longitudinal study33.  Another longitudinal study compared oral and non-oral 
therapy31. Women who used transdermal HT had statistically significant greater 
IMT than women who used oral HT after four years31.  Two out of three cross-
sectional studies of oral HT use found significantly thinner IMT in HT users10, 32 
although in one study this was only true in the long term (> 2 years) HT users10.  
This suggests that the duration of HT use is important for observation of 
detectable changes in IMT.  The Atherosclerosis Risk in Communities (ARIC) study 
and the current study had several similarities: both were cross-sectional, had 
American participants who used oral HT, who were relatively younger and had 
fewer years on HT compared to the positive studies.  ARIC found no significant 
difference in IMT by HT use19, as the current study did.  The ARIC study also had 
undefined HT regimen because the regimen was predetermined by the woman 
and her physician prior to the study.  Selection bias may be present in both 
studies since women who chose to go on HT or continue HT may have been 
different than those who did not.  Longitudinal studies of the affect of HT on IMT 
progression have had mixed results6, 29-31, 33. Some have found no differences in 
IMT progression in HT users and non users29, 31, others have observed slower 
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progression in IMT in HT users than in HT non users6, 30, 33. The longitudinal study of 
oral therapy that did not find a difference in IMT progression in HT users and non-
users had 1 year of follow-up29. 
 
Three studies evaluated differences in HT and IMT in women by age10, 11, 32.  The 
women were dichotomized into younger vs. older (using 55 or 60 as the age cut-
point) significant differences in IMT were observed only in the older women who 
had longer use of HT than the younger women10, 11, 32. This may suggest that the 
effects of estrogen on IMT are evident after long-term use.     
 
Current smoking was associated with a smaller AD in the current study; this is 
contrary to the findings of the Atherosclerosis Risk in Communities (ARIC) Limited 
Access Data study13 that included men and women.  McGarth et al observed 
smokers that used HT had significantly thinner IMT (0.65±0.01 mm) than HT non-
users (0.75±0.01 mm, p=0.002); there was no significant difference observed in 
non-smokers (0.68±0.01 HT users v 0.70±0.03 non-users, p=0.7)32. The McGarth 
study suggests that these findings may be the result of estrogen’s effect on the 
vasculature of smokers, who are usually discouraged from using HT due to the 
risk of thrombosis32.  Other explanations are the vasoconstrictive properties of 
cigarette smoking37-39 and the physiologic changes of the composition of the 
artery wall with age, and the number of pack years of cigarette use.   
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Strengths of this study are that it fills a gap in the literature because it is one of 
the first to evaluate AD and HT, the methods used are valid and reliable, the lab 
that performed the ultrasound measures has high quality control, the study 
population is well defined. The contribution of the adventitia to vascular function 
has been largely ignored23.  This is evident in the scarcity of literature that 
evaluates the measure. High resolution B-mode ultrasound is a valid and reliable 
detector of structural atherosclerotic changes of the arterial walls40. The 
ultrasound measures in this study were performed with excellent reproducibility 
and continuous quality control to ensure the data obtained is reliable and valid. 
The ultrasound technicians were all certified and recertified every 6 months.  The 
study sample is a well defined population of racially diverse postmenopausal 
women from the Allegheny County and surrounding areas of western 
Pennsylvania.   
 
A limitation of this study is that the HT regimen was varied since the dose, 
hormone composition (estrogen only or estrogen plus progestin) and form were 
chosen prior to the study by the participant and her health care provider.  The 
main type of HT was oral.  One study observed that transdermal HT had greater 
effects on IMT than oral HT31.  A standard dose and regimen of HT would be 
easier to evaluate and compare to previous studies. This would likely be 
especially true for the IMT results that were not significant in this study.  Another 
limitation is that the adherence to HT and the level of estrogen or estradiol in the 
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users and non users was not assessed in this study.  Although the women on HT 
reported use we do not know their adherence rates or the amount of estrogen 
metabolites during the ultrasound measurements.  In the future, assessment of 
estradiol levels should be included for better understanding. 
 
In conclusion, these data suggest that HT use affects the vasculature in the early 
postmenopausal period.  AD is important in assessing vascular changes and 
should be evaluated with lumen diameter and intima media thickness to 
provide a more complete story of vascular response and health.   
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3.9       TABLES FOR CHAPTER 3 
 
Table 3.1 Baseline demographic, anthropometric and health characteristics of 
WOMAN cohort by HT use 
 Non Users (n=197) Users (n=294)  
 mean ± standard deviation or % p-value* 
Age, years 57.4 ± 2.9 56.7 ± 2.9 0.006 
African American Race, % 16.9 7.2 0.008 
Systolic Blood Pressure, mmHg 123.6 ± 13.0 123.7 ± 13.4 0.899 
Diastolic Blood Pressure, mmHg 76.7 ± 7.6 76.1 ± 8.0 0.349 
Pulse Pressure, mmHg 46.8 ± 10.5 47.7 ± 10.8 0.335 
Body Mass Index, kg/m2 30.7 ± 4.0 30.7 ± 3.6 0.793 
Weight, kg 81.8 ± 11.6 81.4 ± 11.3 0.849 
Height, cm 163.3 ± 5.6 162.9 ± 5.9 0.642 
Waist circumference, cm 105.4 ± 11.8 105.9 ± 10.7 0.520 
Cholesterol, mg/dL 223.1 ± 29.0 212.5 ± 26.7 0.0002 
High Density Lipoprotein, mg/dL 58.9 ± 13.7 61.4 ± 14.4 0.052 
Low Density Lipoprotein, mg/dL 137.1 ± 26.0 122.1 ± 22.8 <0.0001 
Triglycerides, mg/dL 135.6 ± 63.5 146.3 ± 80.2 0.222 
Glucose, mg/dL 97.3 ± 9.0 93.8 ± 9.0 <0.0001 
Insulin, mg/dL 14.6 ± 7.1 13.0 ± 6.4 0.004 
Current Cigarette Smoker, % 8.1 5.1 0.181 
Antihypertensive Medications, % 25.9 21.4 0.251 
*chi-square for categorical, t-test for continuous 
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 Table 3.2 Baseline subclinical measures of cardiovascular disease of WOMAN 
cohort by HT use 
 Non Users   
(n=197) 
Users                         
(n=294) 
 
 mean ± standard deviation or % p-value* 
Adventitial Diameter, mm 6.9 ± 0.54 6.8 ± 0.52 0.001 
Lumen Diameter, mm 5.4 ± 0.48 5.3 ± 0.46 0.002 
Intima Media Thickness, mm 0.72 ± 0.10 0.72 ± 0.09 0.900 
Presence of Plaque, % 30.5 29.6 0.838 
*chi-square for categorical, t-test for continuous 
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 Table 3.3 Univariate linear regression showing the association of demographic & 
cardiovascular risk factors with common carotid artery adventitial diameter 
                                   Model  
 β Standard Error p-value 
Hormone Therapy Use -0.157 0.048 0.001 
Age, years 0.017 0.008 0.037 
African American Race -0.187 0.076 0.014 
Systolic Blood Pressure, mmHg 0.007 0.002 <0.0001 
Diastolic Blood Pressure, mmHg 0.003 0.003 0.410 
Pulse Pressure, mmHg 0.010 0.002 <0.0001 
Body Mass Index, kg/m2 0.031 0.006 <0.0001 
Weight, kg 0.013 0.002 <0.0001 
Height, cm 0.016 0.004 <0.0001 
Waist Circumference, cm 0.009 0.002 <0.0001 
Cholesterol, mg/dL 0.001 0.001 0.435 
High Density Lipoprotein, mg/dL -0.000 0.002 0.991 
Low Density Lipoprotein, mg/dL 0.001 0.001 0.338 
Triglycerides, mg/dL -0.000 0.000 0.631 
Glucose, mg/dL 0.009 0.003 0.001 
Insulin, mg/dL 0.012 0.004 0.001 
Current Cigarette Smoker -0.205 0.098 0.037 
Antihypertensive Medication Use 0.132 0.057 0.020 
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Table 3.4 Multivariable linear regression of factors associated with common 
carotid artery adventitial diameter 
 Model 
 β Standard Error p-value 
Hormone Therapy Use -0.137 0.047 0.004 
Age, years 0.013 0.008 0.106 
African American Race -0.049 0.074 0.503 
Pulse Pressure, mmHg 0.008 0.002 0.0002 
Weight, kg 0.012 0.002 <0.0001 
Current Cigarette Smoker -0.180 0.093 0.052 
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4.1 INTRODUCTION 
 
Sleep apnea is a cycle of disordered breathing when the airway is narrowed or 
closed causing disrupted and fragmented sleep. It is associated with 
cardiovascular disease, obesity, high blood pressure and diabetes1-9.  A small 
(n=24), all-male, randomized-control trial of severe obstructive sleep apnea 
patients showed evidence that 4-month treatment with the standard of care for 
sleep apnea (continuous positive airway pressure) reduced daytime and 
nighttime diastolic blood pressure, C-reactive protein and carotid-femoral pulse 
wave velocity10.  This implies that standard treatment of sleep apnea in men 
with severe obstructive sleep apnea may improve vascular health. The majority 
of research on sleep apnea has been in children, adolescents, middle 4, 6, 11, 12 
and older adults13; however, few studies have assessed young adults between 
20 and 458.   
 
Snoring is a form of sleep disordered breathing and may also be a marker of 
undiagnosed sleep apnea and its cardiovascular consequences.  Snoring14-17 
and other types of sleep disordered breathing (often associated with sleep 
apnea)1, 6-8, 18-20 have been linked to CVD.   
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There is a U-shaped relationship between higher risk of all-cause mortality and 
short sleep duration (<6 hours) and long sleep duration (>8 hours)21.  Data from 
two cohort studies of men and women from the United States and the United 
Kingdom found that short sleep duration (<6 hours) was correlated to obesity 
and poor health, while long sleep duration (>8 hours) was associated with 
comorbidities22. An observational cohort study of young adults (35-47 years) with 
5-year follow-up found that those with longer sleep duration had a reduced risk 
of coronary artery calcium23. 
 
The purpose of this study is to determine whether baseline sleep quality and 
sleep apnea risk were associated with measures of vascular health in young 
adults, 20-45 years old in an ongoing clinical trial. The measures used were 
carotid-femoral pulse wave velocity (cf-PWV), common carotid artery intima 
media thickness (IMT), adventitial diameter (AD) and lumen diameter (LD). 
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4.2 METHODS 
4.2.1 Study Population 
The Slow Adverse Vascular Effects (SAVE) study is a single-center, randomized-
controlled, clinical trial designed to determine the vascular effects of a lifestyle 
intervention for weight loss, increased physical activity and sodium reduction in 
overweight and moderately obese young adults.  The study recruited over 300 
eligible men and women from Allegheny County, Pennsylvania and surrounding 
counties between March 2007 and May 2009 using direct mailing as the primary 
recruitment method.  Eligible participants were between 20 and 45 years of 
age, overweight or obese (a body mass index (BMI) between 25.0 and 39.9 
kg/m2) and physically inactive. Adults were ineligible if they were exercising > 3 
hours per week for at least 8 of the past 12 months, diabetic, hypertensive,  on 
medication to lower cholesterol, on vasoactive medications or vasoactive 
devices, pregnant or breast feeding or unable to comply with the intervention.  
The study was approved by the University of Pittsburgh’s Institutional Review 
Board and a Data Safety Monitoring Board that met twice a year. 
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4.2.2 Screening 
Each potential participant completed a telephone screen to determine 
eligibility based on age, estimated BMI (based on self-reported height and 
weight), medication use, and physical activity history.  Those eligible based on 
the telephone screen were scheduled for a clinic screening visit.   
 
At the screening visit participants gave informed consent for screening.  
Volunteer contact information, and a brief demographic form were returned 
and medication use was reported.  The demographic form provided self-
reported date of birth, gender, race, ethnicity, history of cigarette smoking, and 
history of alcohol use.   
 
Weight was measured in kilograms with a balance scale.  Height was measured 
in centimeters by a stadiometer and BMI was calculated as weight in kg/ height 
in m2.  Waist circumference was measured twice against the skin in centimeters 
at the narrowest circumference between the ribs and the iliac crest. If the waist 
circumference measures were within two centimeters the values were 
averaged for waist circumference; if they were not waist circumference was re-
measured a third time and the two closest measurements were averaged.  
Blood pressure was measured after the participant sat quietly for 5-minutes with 
their feet flat on the floor using a standard protocol with a mercury 
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sphygmomanometer. Three measurements were taken 30 seconds apart; the 
average of the last two measurements was used.   
4.2.3 Laboratory Tests 
A 12-hour fasting blood draw was completed at the screening visit for each 
participant.  Serum glucose was quantitatively determined by an enzymic 
determination procedure similar to that described by Bondar and Mead24.  Total 
cholesterol was determined using the enzymatic method of Allain et al25.  High 
density lipoprotein (HDL) cholesterol was determined after selective 
precipitation by heparin/manganese chloride and removal by centrifugation of 
very low density (VLDL) and low density lipoprotein (LDL)26.  The HDL cholesterol 
was measured enzymatically.  Triglycerides (TG) were determined enzymatically 
using the procedure of Bucolo et al27. LDL cholesterol was calculated indirectly 
using the Friedewald28 equation: LDLc = Total cholesterol - HDLc - 0.2 (total TG) 
(Not used if total TG > 400 mg/dL).   
4.2.4 Sleep Questionnaires 
Sleep habits, duration and quality including snoring were assessed using two self-
administered questionnaires: the Pittsburgh Sleep Quality Index (PSQI)29 and 
Berlin Sleep Questionnaire (BSQ)30. 
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The PSQI was developed to distinguish good and poor sleepers based on 
perceived sleep quality29.  The self-administered questionnaire has 26-items, and 
is simple to interpret.  The questionnaire has been shown to be reliable and 
valid31, 32.  Each of the seven categories is scored and a composite score is 
determined with a range from 0 to 21.  Validation of the questionnaire identified 
a low score (< 5) is associated with good sleep quality and a high score (> 5) is 
associated with poor sleep quality. This analysis defines good vs. poor sleep 
quality using the < 5 cut point.   
 
The BSQ was designed to determine sleep apnea risk29.  It is self-administered 
and simple to administer and interpret.  The questionnaire has been shown to be 
reliable and valid33.  The questionnaire has three categories: habitual snoring, 
tiredness during the day or daytime dysfunction, and obesity and hypertension.  
The BSQ defines obesity as BMI > 30 kg/m2. The categories are scored and 
summed for a total score that ranges from 0 to 329.  A score < 1 reflects a low risk 
for sleep apnea and a score > 1 reflects a high risk for sleep apnea.  The data is 
evaluated based on these two cut points: low and high risk. 
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4.2.5 B-mode Ultrasound Measurements 
B-mode ultrasound measurements were scheduled as part of baseline visits.  All 
ultrasound tests were conducted by trained, certified lab technicians at the 
University of Pittsburgh Department of Epidemiology’s Ultrasound Research 
Laboratory (URL).  All URL sonographers were re-certified every six months.   
 
Cf-PWV was measured using the Complior Pulse Wave Velocity Machine 
(Artect, VAB00001).  Cf-PWV was measured by taking simultaneous recordings of 
the pulse waves from the right common carotid and right femoral artery using 
mechanotransducers while the participant was in supine position.  Cf-PWV was 
calculated by dividing the distance between transducers by the time of pulse 
wave travel.  Output from the transducers was captured and processed using 
the Complior SP system.  Three data collection runs were performed, each 
obtaining an average of ten pairs of simultaneously recorded pulse waves.  The 
between-tech intraclass correlation coefficient was 0.78-0.91 and within-tech 
intraclass correlation coefficient were 0.88-0.95 for cf-PWV. 
 
Common carotid artery IMT, AD and LD were measured using the Antares 
machine (Siemens, Sonoline) with a 5-MHz linear array transducer.  At the 
baseline visit, images were digitalized from the near and far walls of the distal 
common carotid artery (one centimeter proximal to the carotid bulb), the 
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carotid bulb (the point at which the near and far walls of the common carotid 
artery were no longer parallel to the tip of the flow divider), and the first 1 cm of 
the internal carotid artery (from the tip of the flow divider).  IMT was defined as 
the distance from the lumen-intimal interface to the medial-adventitial 
interface.  AD was defined as the distance from the adventitial-medial interface 
on the near wall to the medial-adventitial interfaces on the far wall.  LD was 
defined as the distance from the intima-lumen interface of the near wall and 
the lumen-intima interface of the far wall.    The interfaces were traced 
electronically over the respective areas and a computer generated 
measurement was obtained for each pixel in the area of interest; these 
measurements were averaged to determine the IMT, AD and LD used for this 
analysis.  The between-tech intraclass correlation coefficient was 0.89-0.99 for 
average IMT. 
4.2.6 Statistical Methods 
All analyses were based on cross-sectional baseline data using SAS v9.1 (SAS 
Institute, Cary, NC). Preliminary analysis showed the relationship between sleep 
measures and CVD measures differed by sex (data not shown), therefore all 
analyses were stratified by gender. The mean (for normal continuous variables), 
the median (for non-parametric continuous variables), or the percent (for 
categorical variables) were determined for the demographic, anthropometric 
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and health characteristics of the population. The Chi-square test for categorical 
and the Wilcoxon rank sum test for continuous variables were used to test for 
differences in sleep characteristics and subclinical CVD measures between  
men and women. General Linear Modeling was used to test whether self-
reported sleep quality or sleep apnea risk were related to the subclinical CVD 
measures controlling for potential confounders age, and systolic blood pressure.  
It was decided a priori if sleep quality, determined by the PSQI, or sleep apnea 
risk, determined by the BSQ, were related to any subclinical CVD measure, 
additional analyses would be performed to determine which aspects of sleep 
quality or risk for sleep apnea were related to the subclinical CVD measures.   
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4.3 RESULTS 
Most of the participants were female (77.4%) and Caucasian (84.0%).  The 
average age was 38 years and mean BMI was 33.1 kg/m2 (Table 4.1).  The 
percent of those with poor sleep quality was not statistically different in men and 
women (Table 4.2).  However, men reported a shorter sleep duration than 
women (p=0.0055, Table 4.2). A higher percent of men had high risk sleep 
apnea scores (63%) than women (49%) (p=0.0281, Table 4.2).  As expected men 
had higher median cf-PWV (7.9 mm/s, 7.6 mm/s), thicker IMT (0.62 mm, 0.59 
mm), larger AD (7.4 mm, 6.8 mm) and larger median LD (6.1  mm, 5.6mm) than 
women (all p<0.05, Table 4.2).  
 
There was no difference in subclinical CVD measures between those who had 
poor sleep quality and those who had good sleep quality determined by the 
PSQI (data not shown).   
 
Women at high risk for sleep apnea had higher IMT, larger AD and higher cf-
PWV than women at low risk for sleep apnea (data not shown).  These results 
were attenuated and lost significance when the model adjusted for age and 
SBP (Table 4.3). In men, AD and LD were significantly larger in those at high risk 
59 
for sleep apnea; these results remained robust after adjustment for age and SBP 
(Table 4.3).   
 
Next, snoring (at least once/month vs. not snoring in the last month) and the 
“tiredness during the day or daytime dysfunction” component of the BSQ, were 
examined to determine their relationship with subclinical CVD measures.   
 
Those who reported snoring had significantly worse subclinical CVD measures 
than those who did not report snoring; the tiredness during the day/daytime 
dysfunction component was not related to the subclinical CVD measures (data 
not shown).  Snorers were significantly older and had higher BMI and blood 
pressure than non-snorers (all p <0.05, data not shown).   
 
Women had no differences in IMT, AD, LD or cf-PWV based on snoring status with 
or without adjustment for age and SBP (Table 4.4).  In men, AD and LD were 
higher in the snorers than the non-snorers after adjustment for age and SBP 
(Table 4.4). 
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4.4 DISCUSSION 
This study of overweight and obese young adults found that even after 
adjustment for age and SBP, men at high risk for sleep apnea and men that 
snored had significantly larger AD and LD than men at low risk for sleep apnea 
and non-snorers.  In women, none of the subclinical CVD measures were 
significantly different by sleep apnea risk or snoring status after adjustment for 
age and SBP. Baseline self-reported sleep quality was not related to any of the 
subclinical CVD measures assessed in the SAVE participants.  
 
The analyses investigating aspects of the BSQ and subclinical CVD measures 
showed snoring was significantly related to a worse cardiovascular profile and 
poorer vascular health.  Snorers had significantly higher BMI and higher blood 
pressure.  Obesity and high blood pressure are associated with sleep apnea.  
Lee et al objectively measured snoring in a cross-sectional study of Australian 
adults (mean age 58.2±7.9); objectively measured heavy snoring was 
associated with higher BMI and greater prevalence of hypertension34.  Heavy 
snorers also had a higher prevalence of carotid plaque measured by B-mode 
ultrasound34.  In the current study, AD and LD were significantly larger in male 
snorers; but not in females. There were few women in the moderate (n=10) and 
heavy (n=5) snoring strata compared to men (n=15 in both groups), thus Lee et 
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al did not evaluate the results by gender34.  The differential effect of snoring on 
the vasculature by gender in the current study suggests further research is 
needed. 
 
Snoring may be a risk factor for carotid disease.  Animal studies in rats and 
rabbits help explain some biological mechanisms between snoring and carotid 
disease. These studies provide evidence that vibrational pressure waves to travel 
from the upper airway to the carotid artery35, and chronic vibrational energy 
damages vascular cells35-38.  The vibrations act as mechanical stress to the 
artery. Managing arterial stress is the role of the adventitia which may explain 
the significance of AD observed between snorers and non-snorers in men in the 
current study. These vibrations also destroy vascular smooth muscle cells38, the 
main component of the media layer of the artery wall39 and damage 
endothelial cells40 that compose the intima or inner layer of the artery. Thus, the 
independent association of AD with snoring after controlling for age and SBP in 
the current study is supported by the biological mechanisms observed in 
animals.   
 
Snoring is a form of sleep disordered breathing and may also be a marker of 
undiagnosed sleep apnea and its cardiovascular consequences.  Snoring14-17 
and other types of sleep disordered breathing (often associated with sleep 
apnea)1,6-8, 18-20 have been linked to CVD.  A subsample of the Nurses’ Health 
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study found that occasional snorers had a 20% higher risk of CVD, and regular 
snorers a 33% increased risk of CVD than non-snorers in an 8 year longitudinal 
study of women who were free of CVD at baseline14.  
 
Strengths of this study were that the population was a well defined sample of 
community-dwelling young adults; assessment of subclinical measures was of 
high quality by certified, trained sonographers & technicians.  Limitations of this 
study were the subjective nature of the questionnaires and the small number of 
men, and simple snoring versus sleep apnea cannot be distinguished from the 
BSQ.   
 
In conclusion, these findings suggest overweight and obese young adults at high 
risk for sleep apnea and those who snore have early adaptive changes to the 
vasculature linked to adverse vascular health.   
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4.9 TABLES FOR CHAPTER 4 
Table 4.1 Baseline demographic, anthropometric and health characteristics 
 
 
Women 
(n = 270) 
Men 
(n = 79) 
 mean ± standard deviation, median        
(25th, 75th percentile) or percent 
Age, years 38.0 ± 6.1 37.3 ± 6.1 
Caucasian, % 81.1 93.7 
Body Mass Index, kg/m2 32.7 ± 3.8 33.5 ± 3.7 
Systolic Blood Pressure, mmHg 112.4 ± 10.6 117.1 ± 9.1 
Diastolic Blood Pressure, mmHg 71.9 ± 8.5 76.6 ± 8.3 
Glucose, mg/dL 94.2 ± 8.2 99.6 ± 7.3 
Current Cigarette Smoker  8.9 11.4 
Total Cholesterol, mg/dL 201.0 (178,226) 200.0 (175,222) 
HDL Cholesterol, mg/dL 53.7 (45,62) 42.5 (37,47) 
LDL Cholesterol, mg/dL 121.5 (98,144) 124.0 (105,149) 
Triglycerides, mg/dL 105.5 (76,156) 152.0 (110,209) 
HDL High Density Lipoprotein, LDL Low Density Lipoprotein 
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 Table 4.2 Sleep and subclinical CVD characteristics by gender 
 Women 
(n = 270) 
Men 
(n = 79) 
 
 median (25th, 75th percentile) or % p-value 
Amount of sleep*, hours 7.0 (6.0,7.5) 6.5 (6.0,7.0) 0.006 
PSQI Poor Quality Sleepţ, % 48.5 53.2 0.468 
High Risk BSQ scoreţ, % 49.3 63.3 0.028 
Snorersţ, % 46.0 67.1 0.001 
Intima media thickness*, mm 0.58 (0.54,0.63) 0.62 (0.57,0.67) 0.001 
Adventitial Diameter*, mm 6.8 (6.5,7.1) 7.4 (7.1,7.6) <0.0001 
Lumen Diameter, mm 5.6 (5.3,5.9) 6.1 (5.9,6.4) <0.0001 
Cf-Pulse Wave Velocity*, mm/s 7.6 (6.9,8.4) 7.9 (7.2,8.6) 0.017 
* Wilcoxon rank sum test, ţChi-square test, 
BSQ Berlin Sleep Questionnaire, cf carotid-femoral, CVD Cardiovascular Disease, 
PSQI Pittsburgh Sleep Quality Index  
 
71 
Table 4.3 Low risk and high risk for sleep apnea & subclinical CVD measures by gender 
 Women  Men  
 Low Risk SA 
(n=137) 
High Risk SA 
(n=133) 
 
Low Risk SA 
(n=29) 
High Risk SA 
(n=50) 
 
 median (25th, 75th percentile) p-value* median (25th, 75th percentile) p-value* 
IMT, mm 0.56 (0.53,0.62) 0.60 (0.44,0.66) 0.434 0.61 (0.54,0.66) 0.63 (0.57,0.67) 0.165 
AD, mm 6.7 (6.4,7.0) 6.8 (6.5,7.1) 0.144 7.4 (6.9,7.5) 7.4 (7.2,7.7) 0.012 
LD, mm 5.6 (5.3,5.8) 5.6 (5.3,5.9) 0.177 6.1 (5.7,6.3) 6.1 (6.0,6.4) 0.020 
cf-PWV, cm/s 7.3 (6.8,8.2) 7.8 (7.2,8.7) 0.178 7.5 (7.2,8.2) 8.1 (7.5,8.7) 0.276 
*p-value from a general linear model controlling for age and systolic blood pressure 
AD Adventitial Diameter, cf-PWV carotid-femoral Pulse Wave Velocity, CVD Cardiovascular Disease, IMT 
Intima Media Thickness, LD Lumen Diameter, SA Sleep Apnea 
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Table 4.4 Snoring status & subclinical CVD measures by gender 
  Women  Men  
 
Non-snorers 
(n=146) 
Snorers 
(n=124)   
Non-snorers 
(n=26) 
Snorers 
(n=53) 
 
 
 median (25th, 75th percentile) p-value* median (25th, 75th percentile) p-value* 
IMT, mm 0.57 (0.53, 0.62) 0.60 (0.54, 0.65) 0.738 0.61 (0.54, 0.67) 0.62 (0.57, 0.67) 0.684 
AD, mm 6.7 (6.4, 7.0) 6.8 (6.5, 7.1) 0.628 7.4 (6.9, 7.5) 7.4(7.2, 7.7) 0.034 
LD, mm 5.6 (5.3, 5.9) 5.6 (5.3, 5.9) 0.672 6.1 (5.7, 6.3) 6.1 (5.9, 6.4) 0.030 
cf-PWV, cm/s 7.5 (6.8, 8.3) 7.7 (7.1, 8.6) 0.909 7.7(7.3, 8.4) 8.0 (7.2, 8.6) 0.697 
* p-value from a general linear model controlling for age and systolic blood pressure 
AD Adventitial Diameter, cf-PWV carotid-femoral Pulse Wave Velocity, CVD Cardiovascular Disease, IMT 
Intima Media Thickness, LD Lumen Diameter 
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5.1 INTRODUCTION 
Atherosclerosis is a disease of the arteries that begins as a fatty cholesterol 
streak in the inner wall of the artery; regression or further development is 
dependent upon several factors. Subclinical atherosclerosis is asymptomatic 
and precedes clinical cardiovascular disease (CVD) events such as myocardial 
infarction1-3 and stroke2, 4-7. Subclinical atherosclerosis can be detected using 
several non-invasive, reliable and valid, B-mode ultrasound measures including 
pulse wave velocity (PWV)8, 9, intima media thickness(IMT)10, 11, adventitial 
diameter(AD)12, 13 and lumen diameter(LD)12, 14.   
 
Although, thickening of the intima-media layers15 and arterial stiffening16, 17 are 
characteristic of normal aging; they are also associated with atherosclerosis10, 
CVD risk factors and CVD7. There is evidence that behavioral factors such as 
smoking18, 19, and poor dietary habits19 influence atherosclerotic progression.  
Physical activity (PA) has been associated with CVD benefit20-22. Potential 
mechanisms are the influence it has on arterial remodeling. Cross-sectional 
studies of exercise and physical activity show higher PWV in sedentary or less 
active groups, indicating more arterial stiffness than active groups17, 23, 24.  
Longitudinal studies have found no difference in change in PWV between 
active and less active groups25, 26. Inconsistent results from prior studies may be 
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explained by differing populations and control groups, type, intensity and 
duration of the PA intervention. 
 
The Lifestyle Interventions and Independence for Elders (LIFE) project was a 
randomized controlled pilot study designed to determine if a PA intervention 
compared to a successful aging (SA) education-only control group could 
improve physical function and decrease disability in sedentary older adults at 
risk for mobility disability27. Post intervention participants in the PA group had 
significantly better performance on measures of physical function, lower rates of 
mobility disability, and were more physically active than those in the SA group28. 
An ancillary study of LIFE was developed to evaluate whether the PA 
intervention would affect subclinical CVD progression. The main outcome was 
change in arterial stiffness measured by carotid-femoral PWV. Change in 
common carotid artery (CCA) IMT, AD and LD were secondary outcomes.  
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5.2 METHODS 
5.2.1 Population 
Four hundred twenty-four eligible sedentary men and women were recruited 
between April 2004 and February 2005 at four field centers located at the 
Cooper Institute in Dallas, TX, Stanford University in Palo Alto, CA, University of 
Pittsburgh in Pittsburgh, PA and Wake Forest University in Winston-Salem, NC for 
the LIFE randomized controlled pilot study28.  Eligible participants were sedentary 
(reported fewer than 20 minutes/week of structured physical activity in the last 
month), 70-89 years of age, able to walk 400-meters, at risk for mobility disability 
(had a Short Physical Performance Battery (SPPB) score <9), living in one of the 
study areas, willing to provide informed consent, and able to complete a 
behavioral run-in28.  The behavioral run-in was a 1-week, pre-randomization test 
of compliance; the participants were asked to complete a daily food diary of 
the quantity and kind of fruits and vegetables consumed and a physical activity 
diary of the types and frequency of physical activity27.  Successful completion of 
the behavioral run-in was defined as completing the diary at least 6 of the 7 
days27.  Participants were randomized to the moderate PA group or the SA 
education-only control group after successfully completing the run-in and 
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baseline assessment. The study was approved by the institutional review boards 
of each institution.   
 
In order to study how a PA intervention influenced the risk of CVD all LIFE 
participants at the University of Pittsburgh were asked to participate in an 
ancillary study which included measures of subclinical CVD.  Of 106 participants, 
52 agreed to participate and provided informed consent.    
5.2.2 Screening, Baseline Assessment 
The screening process consisted of a telephone interview, SPPB, a medical 
screening, a 400-meter walk test and the behavioral run-in29.  First, the telephone 
screening obtained information for initial eligibility: verbal informed consent to 
be screened, age, zip code, physical activity level and health status29.  Eligible 
volunteers were then scheduled for a clinic visit where written informed consent 
was obtained and the SPPB was completed29.  Volunteers with SPPB score of >10 
were asked to undergo medical screening29. Written informed consent for the 
main study, demographic information, socioeconomic status, lifestyle habits, 
physical function, physician-diagnosed disease information, medication 
inventory and health-related quality of life were self reported and 
anthropometric measurements, blood pressure, radial pulse, grip strength, an 
electrocardiogram, physical activity (assessed by the Community Healthy 
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Activities Model Program for Seniors (CHAMPS)30 questionnaire) and cognition 
(assessed using the Mini-Mental State Examination) were objectively measured 
at the medical screening visit27, 28.  Abnormal electrocardiogram tests were 
reviewed by the field center physician29 who determined whether the volunteer 
was eligible.  Volunteers deemed eligible based on the medical screening were 
then given the 400-meter walk test29.  Next, eligible volunteers who successfully 
completed the 400-meter walk (<15 minutes, without the use of cane or assistive 
device) were given instructions for completing the compliance run-in; those with 
unsuccessful completion were given one additional opportunity.  Randomization 
occurred after successful completion of the run-in and was stratified by gender 
and site. 
5.2.3 6-month Follow-up Assessment 
The six-month assessment consisted of the same measures completed at the 
baseline visit minus collection of demographic information, socioeconomic 
status, and lifestyle habits, the Mini-Mental State Examination, physical exam, 
and electrocardiogram27.  The subclinical CVD measures were scheduled the 
same day as the 6-month follow-up clinic assessment for the main LIFE pilot 
study. 
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5.2.4 Ultrasound Measures 
Carotid-femoral PWV was measured by using two 8-10  MHz unidirectional 
transcutaneous Doppler flow probes model 810-a (Parks Medical Electronical, 
Aloha, OR) placed at the right carotid and femoral arteries with the participant 
in the supine position9.   Simultaneous recordings of the pulse waves and 
electrocardiogram output from the carotid and femoral arteries were obtained 
and stored on a computer for later reading9.  PWV was calculated by dividing 
the distance between transducers by the time of pulse wave travel. When the 
recordings were read, three cycles of pulse waves were averaged to obtain 
PWV. 
 
CCA IMT, AD, and LD were assessed by B-mode ultrasound using a Sonoline 
Antares duplex scanner (Siemens, Malvern, PA) with a 5-MHz linear array 
transducer.  Images were taken on the right CCA of the near and far walls of the 
distal CCA 1 cm proximal to the carotid bulb.  IMT was defined as the distance 
from the lumen-intimal interface to the medial-adventitial interface.  Computer 
generated measurements were obtained from the electronically traced lumen-
intimal and medial-adventitial interfaces over the areas of interest; these 
measurements were averaged to determine IMT. AD was defined as the 
distance from the adventitial-medial interface on the near wall to the medial-
adventitial interfaces on the far wall.  Computer generated measurements were 
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obtained from the electronically traced adventitial-medial and medial-
adventitial interfaces; these measurements were averaged for the 
determination of AD. LD was defined as the distance from the intima-lumen 
interface of the near wall to the lumen-intima interface of the far wall.  
Computer generated measurements were obtained from the electronically 
traced intima-lumen and lumen-intima interfaces; these measurements were 
averaged to determine LD.  
5.2.5 Intervention  
The LIFE-pilot interventions are described in more detail elsewhere27.  The PA 
intervention had three phases: adoption, transition and maintenance. A one-on-
one, 45-minute introduction session was conducted by an exercise physiologist 
to explain the intervention and answer questions prior to the adoption phase27. 
The PA group participated in one-on-one, center based, 60 minute sessions of 
aerobic (40 minutes), strength (10 minutes), balance and flexibility (10 minutes) 
exercises three times a week for the 1st eight weeks of the intervention27.  At 
week four home based exercises were incorporated once a week through week 
five, and twice a week in weeks six through eight. During the transition period, 
weeks 9-28, participants attended two more center based sessions and 
completed three home based sessions per week27.  There were also 10 group 
counseling sessions between weeks one and eight to emphasize physical 
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activity and the prevention of mobility disability27. The maintenance phase 
included monthly center based sessions and home sessions 5 times a week until 
the end of the 12-month intervention27.  Participants were encouraged to 
participate in at least 150 minutes of moderate intensity physical activity per 
week27. Walking was the main mode of exercise for its ease and safety.  
 
The SA group met weekly for the first 26 weeks then monthly until the 12-month 
follow-up.  The intervention was given in a small group setting; participants were 
provided relevant health information for older adults including nutrition, 
medication use, foot care and preventive care services27, 28. In addition, upper 
extremity stretching exercises were led by the group leader for 5-10 minutes at 
the end of each session27, 28. 
5.2.6 Statistical Methods 
Wilcoxon-rank sum tests and Chi-square tests were used to determine 
differences in baseline characteristics between the intervention groups.  
Wilcoxon signed rank tests were used to evaluate progression of subclinical CVD 
within groups. Change in subclinical measures was determined by subtracting 
baseline values from 6-month values.  General Linear Models (GLM) were used 
to assess between group differences in change in subclinical measures.  Models 
were run for each subclinical measure adjusting for the applicable baseline 
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subclinical measure, race, gender, age, BMI, pulse pressure, history of 
hypertension and history of diabetes.  A p-value < 0.05 was considered 
statistically significant.  All analyses used intention-to-treat group assignments 
and were completed using SAS v9.1 (SAS Institute Inc., Cary, NC). 
 
Post-hoc sample size and power calculations were made using PASS 2008 
(NCSS, Kaysville, UT) to determine the effect size that could be detected given 
the sample size of the PA and SA groups. The final sample size for this analysis 
was 38.   
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5.3 RESULTS 
Fourteen of the 52 participants were excluded from analysis due to unusable 
baseline or follow-up subclinical measures.  The reasons for incomplete data 
were difficulty obtaining usable images due to an inability of the participant to 
lie flat (n=11), mechanical error (n=2) and refusal to complete follow-up 
measures (n=1).  
 
The majority of the sample was female (73.4%) and hypertensive (55.3%); 15.8% 
were African American, 18.4% had diabetes and none were current smokers.  
The median (range) age was 78 (70-85) years and BMI was 29.2  kg/m2 (20.1-
44.1).  Eighteen participants were in the PA intervention group and 20 
participants were in the SA education-only group.  Due to the small sample size 
there was inadequate power to detect clinically relevant differences between 
groups in demographic, anthropometric, CVD risk factors or subclinical 
measures at baseline (Table 5.1).  (E.g. a sample size of 18 and 20 allowed us to 
detect an effect size of 0.91 or a difference in proportions of approximately 40-
45% with 80% power.) As a result, none of the variables were statistically different 
between groups (data not shown); however with a larger sample size, 
differences in age, gender, race, pulse pressure, BMI, history of hypertension and 
history of diabetes may have been seen.  Due to our inability to determine 
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statistically significant relationships between these variables and the groups, we 
adjusted all analyses for these covariates. 
 
PWV appeared to decrease between baseline and 6-month follow-up in the PA 
group, although the difference did not reach statistical significance (Table 5.2; 
p=0.08).  Although median change in the SA control group was also lower, 
about half the group had higher values at 6 months. As a result, this change was 
not statically significant (Table 5.2; p=0.64).  The difference in change in PWV 
between groups was significant after adjustment for baseline PWV, age, gender, 
race, pulse pressure, BMI, history of hypertension and history of diabetes (Figure 
5.1).  
 
The PA group had increased AD (p=0.03) and LD (p=0.02) between baseline 
and 6-month follow-up while the SA group had decreased AD (p=0.03) and LD 
did not differ significantly (Table 5.2). The two groups had significantly different 
changes in AD (p=0.003) and LD (p=0.02) in fully adjusted models (Figures 5.2 
and 5.3). 
 
No change was observed in either group between baseline and six month 
follow-up IMT (Table 5.2).  Change in IMT between groups was also insignificant 
(Figure 5.4). 
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5.4 DISCUSSION 
In this study of older adults progression of arterial stiffening (measured by PWV) 
during the 6-month intervention differed by intervention group.  Specifically, the 
PA group had significantly lower PWV than the SA control group.  The PA group’s 
regression of arterial stiffening (median decrease of 257 cm/s) was clinically 
relevant. Although this study found no change in PWV in the SA group (median 
decrease 28 cm/s), longitudinal studies of PWV progression have reported 
increases of 11.1 to 68.3 cm/s per year in normotensive and treated 
hypertensive participants31 and those with impaired glucose, high blood 
pressure, both or neither32.  The PWV findings from the current study are in line 
with the several cross-sectional studies which have found endurance trained 
adults and active healthy adults have lower PWV than their sedentary 
counterparts17, 23, 24.  Endurance trained older men from the Baltimore 
Longitudinal Study of Aging17 and endurance trained postmenopausal women24 
had 30% lower PWV than their sedentary counterparts in two cross-sectional 
studies17, 24.  A cross-sectional study of healthy men and women who were either 
sedentary or active (practiced yoga at least twice a week or aerobic exercise 
at least three times a week over the past year) found that the active 
participants had significantly lower PWV than the sedentary participants23.  
However, two intervention studies have found null results. A randomized cross-
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over study with 8 weeks of moderate intensity cycling and 8 weeks of sedentary 
behavior was conducted in ten adults with untreated isolated systolic 
hypertension (systolic blood pressure >150 mmHg and diastolic blood pressure 
<90 mmHg) did not observe differences in PWV after the sedentary phase 
compared to the PA phase25.  Similarly, a randomized study comparing a 
walking intervention and an active control group (sodium restriction) in 
postmenopausal women with untreated elevated blood pressure (systolic blood 
pressure 130-159 mmHg, diastolic blood pressure > 99 mmHg) did not observe a 
reduction in PWV in the walking group while those in the active control (sodium 
restriction) did26.  However, there were important differences in these studies 
and the current study. These studies were shorter in duration25,26. This may 
suggest changes in stiffness require sustained physical activity for more than 
three months. Both studies also studied untreated hypertensive individuals who 
may be more resistant to arterial changes from short-term increased physical 
activity than normontensive peers25. Additionally, the postmenopausal women 
in the sodium restriction control group had a large reduction in arterial stiffness26. 
Consequently, the effect of physical activity was not compared to sedentary 
behavior alone. 
 
No prior studies, to our knowledge, have included AD in the assessment of PA 
and subclinical CVD.  Thus, our expectations were the PA group would have 
better vascular health, reflected in smaller AD than the SA group. These 
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expectations were based on studies that showed smaller AD was associated 
with better vascular health in younger cohorts. Contrary to our expectations AD 
increased in the PA group and decreased in the SA group. This suggests the 
intervention may have affected vascular remodeling in ways not indicated by 
the more commonly used IMT.  The adventitia is more sensitive to hemodynamic 
changes in the arterial environment than the media and intima layers of the 
artery33.   
 
LD also increased between baseline and six month follow-up in the PA group.  
LD changes observed in the PA group could reflect increased sheer stress, the 
tangential, mechanical force exerted on the vessel from the flow of blood on 
the lumen34, due to increased blood flow induced by physical activity and 
exercise.  A positive association between blood flow and femoral LD has been 
observed in a cross-sectional study comparing sedentary and endurance 
trained men (r=0.39, p<0.001) and a 3-month moderate endurance training 
intervention study of previously sedentary men (r=0.62, p<0.0001)35.  
 
There was neither within group change in IMT nor between group differences in 
change in IMT. Consistent with our results, two cross-sectional studies comparing 
athletes/physically active adults to sedentary adults found no relationship36, 37.  
Active adults who ate a healthy diet had lower IMT than sedentary adults who 
ate an unhealthy diet in a cross-sectional study19.  This relationship was only 
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present in non smokers; diet and activity were not examined separately in this 
study19.  
 
The mechanisms explaining how physical activity and exercise are beneficial to 
arterial aging are not well established38.  A proposed mechanism is that exercise 
and physical activity lower or reverse the effects of age-related vascular 
structural changes, but this mechanism has not been supported with data38.  
The beneficial effects of physical activity may be related to the improvement of 
cardiovascular risk factors such as improved lipid profiles and weight 
management39.  A large prospective study of women suggested inflammatory 
markers like C-reactive protein and fibrinogen, and reduced blood pressure 
explain 33% and 27% of CVD risk reduction associated with physical activity40.   
 
The findings of this study must be interpreted with caution due to the small 
sample size and large variance in 6-month change yielding insufficient power 
for most analyses.  Although activity was significantly higher in the PA group than 
the SA group28, the large variation in 6-month change in arterial stiffening and 
diameter observed in both groups may be associated with the amount or 
intensity of physical activity or health behavior changes adopted by the groups.  
A wider variation of subclinical disease is observed with increasing age9, 41-43. The 
70-89 year olds in this study have a much wider variance of values than studies 
of middle-aged adults.  The goal of the ancillary study was to obtain complete 
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subclinical atherosclerosis measures on 52 participants; we were successful 
obtaining information on 73% of this sample for the measures of AD, LD and IMT 
but only 44% for PWV.  The inability of some participants to lie flat was the main 
reason usable images could not be obtained; the problem was resolved with 
the purchase of a reclining chair.  An additional limitation of the study is 
antihypertensive medication use was not assessed.  Some antihypertensive 
medications are known to alter arterial stiffness44, 45.  Thus, due to the high history 
of hypertension (50% in PA and 60% SA) it is possible there were group 
differences in antihypertensive medication use.   
 
Some strengths of this study include: valid and reliable methods; the lab that 
performed the ultrasound measures consistently exhibits excellent reproducibility 
and procedures for continuous quality control 9, 45, 46; the study population was 
well defined; and a novel measure of vascular health (AD) was used. No 
previous studies have evaluated the relationship between PA and AD which 
may provide information about vascular health and adaptation that is different 
than that indicated by IMT or LD alone. 
 
In conclusion, despite a small sample size we found significant differences in 
change in PWV, AD and LD in older adults assigned to a PA intervention or SA 
control group.  We observed that the PA group experienced regression of 
arterial stiffening but increased arterial diameters. A larger sample size is needed 
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to fully understand what these vascular changes mean in this population, to 
allow adjustment for confounders and to assess gender and racial differences. 
The phase 3, randomized, controlled LIFE study has been funded but currently 
does not include measures of subclinical atherosclerosis. Therefore, there may 
be an opportunity to evaluate this question in a larger sample of participants 
through an ancillary study where measures of subclinical atherosclerosis are 
obtained.  
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5.9 TABLES AND FIGURES FOR CHAPTER 5 
Table 5.1 Baseline characteristics of randomized groups 
 
 
Physical Activity Successful Aging 
(n=18) (n=20) 
 median (25th, 75th  percentile) or % 
Age, years 75.5 (72,80) 78 (74,82) 
Female, % 66.7 80.0 
African American Race, %  11.1 20.0 
Blood Pressure, mmHg   
Systolic blood pressure 139 (121,146) 136 (123,148) 
Diastolic blood pressure 67 (59,76) 68 (64,77) 
Pulse pressure 69 (61,81) 64 (46,72) 
Body mass index, kg/m2 30.3 (28,35) 28.9 (26,32) 
Current Cigarette Smoker, %  0 0 
History hypertension, % 50.0 60.0 
History Diabetes, % 27.8 10.0 
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Table 5.2 Baseline, 6-month and change in subclinical measures by intervention group 
 
Physical Activity 
Median (25th, 75th percentile)   
Successful Aging 
Median (25th, 75th percentile)   
  Baseline 6-month p-val* Change Baseline 6-month p-val* Change 
 
PWV 1158 (965,1304) 951 (820,1289) 0.08 -257 (-371,-6.55) 1072 (896,1384) 1063 (820,1328) 0.64 -28 (-359,181) 
AD 7.93 (7.37,8.86) 8.02 (7.64,9.00) 0.03 0.09 (-0.02,0.26) 7.87 (7.39,8.15) 7.78 (7.20,8.15) 0.03 -0.16 (-0.28,0.02) 
LD 5.95 (5.65,6.57) 6.03 (5.87,6.71) 0.02 0.19 (-0.07,0.27) 5.78 (5.49,6.07) 5.77 (5.39,6.15) 0.20 -0.07 (-0.27,0.09) 
IMT 0.99 (0.86,1.13) 0.95 (0.85,1.05) 0.25 -0.02 (-0.05,0.01) 1.00 (0.92,1.08) 0.97 (0.90,1.11) 0.47 -0.01 (-0.05,0.02) 
* Wilcoxon signed rank  test comparing baseline and 6-month values  
p-val p-value, PWV Pulse Wave Velocity, AD Adventitial Diameter, LD Lumen Diameter, IMT Intima Media Thickness
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Figure 5.1 Box plot of change in pulse wave velocity by intervention group   
 
P-value is from a general linear model controlling for baseline pulse wave 
velocity, race, gender, age, BMI, pulse pressure, history of hypertension and 
history of diabetes 
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Figure 5.2 Box plot of change in adventitial diameter by intervention group   
 
P-value is from a general linear model controlling for baseline adventitial 
diameter, race, gender, age, BMI, pulse pressure, history of hypertension and 
history of diabetes 
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Figure 5.3 Box plot of change in lumen diameter by intervention group   
 
P-value is from a general linear model controlling for baseline lumen diameter, 
race, gender, age, BMI, pulse pressure, history of hypertension and history of 
diabetes 
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Figure 5.4 Box plot of change in intima media thickness by intervention group   
 
 
P-value is from a general linear model controlling for baseline intima media 
thickness, race, gender, age, BMI, pulse pressure, history of hypertension and 
history of diabetes 
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6.0     GENERAL DISCUSSION 
6.1 SUMMARY OF FINDINGS 
 
This dissertation evaluated the effect of lifestyle risk factors on the vascular aging 
process measured by B-mode ultrasound in three cohorts that span the life 
course.  The cohorts were from Allegheny County, Pennsylvania and the 
surrounding Western Pennsylvania area; the participants were overweight or 
obese and predominately female. All of the ultrasound measurements were 
made and read by trained technicians at the Ultrasound Research Lab at the 
University of Pittsburgh.  Each study evaluated common carotid artery intima 
media thickness, adventitial diameter, and lumen diameter.  Chapter 3 also 
evaluated carotid plaque.  Chapters 4 and 5 included carotid-femoral pulse 
wave velocity. 
 
The first cohort (Chapter 3) was composed of postmenopausal women 52-62, 
with a waist circumference > 80 cm, low density lipoprotein cholesterol between 
100 and 160 mg/dL, who were not diabetic, depressed, diagnosed with a 
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psychotic disorder or taking medication for cholesterol in the Women On the 
Move through Activity and Nutrition clinical trial.  The second cohort (Chapter 4) 
was sedentary, 20-45 year old adults who were not hypertensive, diabetic or on 
cholesterol lowering, or vasoactive medications in the Slow Adverse Vascular 
Effects clinical trial.  The third cohort (Chapter 5) was of sedentary, older adults 
70-89 years old who were at risk for mobility disability in the Lifestyle Interventions 
and Independence for Elders pilot study.   
 
Together, the papers in this dissertation, Chapters 3-5, provide evidence that 
lifestyle factors have an impact on vascular health. Hormone therapy users in 
Chapter 3, those with low risk of sleep apnea and non-snorers in Chapter 4, and 
older adults in a moderate physical activity intervention in Chapter 5, had 
significantly different vascular geometry than the hormone therapy non-users, 
those at high risk for sleep apnea, snorers and those in an education only control 
group, respectively. Each study also provides proof that the measurement of 
adventitial diameter is critical for having a comprehensive understanding of the 
vascular remodeling processes that accompany these lifestyle changes.  The 
utility of these measures are consistent across populations at different points 
along the vascular aging continuum. The adaptation of the vasculature was 
often unseen when intima media thickness was evaluated alone; significant 
changes were only captured when adventitial and lumen diameter were 
included.  Examples from Chapters 3, 4 and 5 are provided below. 
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Chapter 3 found current hormone therapy users had significantly smaller 
adventitial diameters and lumen diameters that reflect better vascular health 
than those who were not current users even after adjustment for cardiovascular 
risk factors.  This study shows the importance of measuring adventitial diameter 
when evaluating hormone therapy; the vascular differences observed would 
have been overlooked if only intima media thickness had been measured. Here 
adventitial diameter and lumen diameter provide a more complete picture of 
the vascular differences between the two groups.  
 
Men, in Chapter 4, at high risk for sleep apnea, determined by the Berlin Sleep 
Questionnaire1 had significantly larger adventitial diameter and lumen diameter  
than those at low risk for sleep apnea; these results remained robust after 
adjustment for age and systolic blood pressure. Women at high risk for sleep 
apnea had higher intima media thickness, larger adventitial diameter and 
higher carotid-femoral pulse wave velocity than women at low risk for sleep 
apnea. After adjustment for age and systolic blood pressure the results lost 
significance. Compared to daytime tiredness, snoring was responsible for most 
of the variance observed between sleep apnea risk and subclinical 
cardiovascular disease.  Snoring was associated with poor cardiovascular profile 
reflected in larger adventitial and lumen diameters in men only. These findings 
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provide evidence of differential vascular aging linked to sleep apnea risk and 
snoring in non-diabetic, normotensive, overweight and obese young adults.  
 
In chapter 5, change in pulse wave velocity was different between the 6-month 
physical activity and education-only control intervention groups; with the 
physical activity group experiencing a clinically relevant decline in pulse wave 
velocity. Change in adventitial diameter and lumen diameter between groups 
was also different. However, contrary to expectation adventitial diameter and 
lumen diameter increased in the physical activity group and decreased in the 
control group. There were no differences in change in intima media thickness 
between groups.  These findings reflect vascular remodeling in the adventitial 
and lumen diameters that is undetected when intima media thickness is 
evaluated.  This is yet another example that highlights the value of using 
adventitial diameter.  Despite a small sample size we were able to find 
differences between the groups for carotid-femoral pulse wave velocity, 
adventitial diameter and lumen diameter and clinically meaningful change in 
carotid-femoral pulse wave velocity.  Further study of the effects of physical 
activity on subclinical cardiovascular disease in older adults is needed.   
108 
 
6.2 PUBLIC HEALTH SIGNIFICANCE 
Cardiovascular disease (CVD) is the leading cause of death in the United 
States2.  Although, vascular aging is part of the natural aging process, lifestyle 
choices can modify the trajectory of vascular aging3. Lifestyle choices can 
reverse, slow the progression or accelerate the vascular aging process thus 
changing the CVD risk profile.  Well known traditional CVD risk factors have 
helped target high risk individuals.  However, traditional risk factors for CVD only 
explain about 30% of the risk for an event. Thus additional tools that further 
explain CVD risk are important.  CVD develops over several years beginning as 
fatty streaks in childhood or adolescence4-6.  Carotid intima media thickness has 
become more widely used in epidemiological studies as a surrogate for 
atherosclerosis7.  As such, it has been used as a tool to stratify cardiovascular risk 
of individuals across the subclinical disease spectrum.  Although not as 
commonly used as intima media thickness, lumen diameter has been used with 
intima media thickness to provide a better picture of vascular health8-11.  This 
dissertation provides confirmation that adventitial diameter should be measured 
with intima media thickness and lumen diameter to better target and treat 
those at otherwise hidden risk for cardiovascular disease.  Targeting these 
individuals is very important because they represent a population that is 
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experiencing accelerated vascular aging that may not be detected through 
traditional risk factors alone.  Identification of these individuals will allow earlier 
intervention that can alter the vascular aging process to prevent, slow or delay 
cardiovascular morbidity and / or mortality. This will also impact the burden of 
CVD on the healthcare system, families and the economic infrastructure.  The 
productivity preserved by delaying morbidity by a few years or shortening the 
time of life spent with disability is great.  This is increasingly important as the 
proportion of the American population over 65 years old increases rapidly with 
the baby boomer generation12, 13. 
 
The results of this dissertation have shown that the postmenopausal women with 
acute use of hormone therapy had smaller adventitial diameters reflecting 
better vascular health than those who did not use hormone therapy.  This work 
links the effects of endogenous estrogen14 on the vasculature with those of 
exogenous estrogen.  
 
Young adult men at a high risk for sleep apnea had less favorable vascular 
health profiles than those with a low risk for sleep apnea.  The young adults at 
high risk for sleep apnea reflect those on a steep trajectory to CVD events if their 
risks go unaddressed.  It will be important to identify these young adults early so 
that their risk factors can be reduced with lifestyle choices or treatment. 
Interestingly, carotid adventitial diameter and lumen diameter in men was 
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different by snoring status; snorers had larger diameters than non-snorers.  This 
work expands the literature that connects snoring and carotid artery 
atherosclerosis in middle aged to older men and women15, snoring and 
increased CVD risk factors in men and women16 and increased risk for CVD 
events in middle aged women17. 
 
The LIFE pilot results are important because they suggest that physical activity, 
even in previously sedentary older adults, provides a vascular benefit.  This 
supports the idea that it is never too late to gain cardiovascular benefit from 
physical activity. Older adults in the physical activity group had significantly 
different change in PWV than the older adults in the successful aging control 
group; the regression in vascular stiffness in the physical activity group was 
clinically meaningful.  Differences in change in AD and LD between groups were 
seen in opposite directions than we expected. A lesson learned from this study is 
that we cannot assume the effects of physical activity in older adults resemble 
those of younger adults. Longer duration of physical activity may be necessary 
to observe the expected differences in AD and LD in older adults. The results 
reflect the importance of studying the subclinical cardiovascular changes of 
older adults who participate in physical activity interventions.  
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6.3 FUTURE RESEARCH 
Future research should focus on better understanding the mechanisms that 
explain hormone therapy, sleep apnea risk, snoring and physical activity affect 
the vasculature. Research to quantify the amount, the duration and who is best 
suited for these lifestyle choices is also needed.  These questions are still being 
answered for hormone therapy. It is important to investigate whether lowering 
sleep apnea risk (i.e. snoring, obesity) translates to lowered cardiovascular risk 
over time in young adults.  An important question is what should be done in the 
case of someone with chronic snoring in the absence of sleep apnea. For sleep 
apnea patients that snore, continuous positive airway pressure (CPAP) is the 
standard treatment but is not well tolerated by most patients or their bed 
partners18.  A study of men with sleep apnea found that use of CPAP reduced 
carotid-femoral pulse wave velocity19; a study of the effectiveness in women 
should also be done.  Finding a more acceptable treatment may be a key to 
helping this population of chronic snorers.  The effect increased physical activity 
in older adults also needs to be further investigated.  The changes in adventitial 
and lumen diameter indicated vascular remodeling among those in the 
physical activity group.  
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Adventitial diameter has been neglected in the literature and in common 
practice when carotid measurements are made.  The body of research 
supported by this dissertation shows that adventitial diameter provides 
information to present a complete picture of vascular health.  Adventitial 
diameter is very easy to measure, it can be calculated if intima media thickness 
and lumen diameter are available (Equation 6.1).  The common practice of 
digitally recording carotid ultrasonography would allow re-reading the images 
to measure adventitial diameter if intima media thickness and lumen diameter 
were not both measured.  Prior studies of lifestyle factors that used carotid 
measures should evaluate the results when adventitial diameter is included.  This 
is especially important in studies that had null findings because intima media 
thickness cannot capture the subtle changes in the adventitia.  Thus, future 
studies of lifestyle interventions that use carotid measures as the outcome should 
include adventitial diameter.   
 
 
Equation 6.1 To calculate adventitial diameter from lumen diameter and intima 
media thickness 
 
Adventitial diameter = lumen diameter + intima media thickness x 2 
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